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N6-isopentenyladenosine (iPA) is a modified adenosine characterized by 
an isopentenyl chain derived by dimethylallyl pyrophosphate (DMAPP), 
an intermediate of the metabolic pathway of mevalonate, that is known to 
be deregulated in cancer. 
iPA is an endogenous isoprenoid-derived product present in mammalian 
cells as a free nucleoside in the cytoplasm, or in a tRNA-bound form, 
displaying well established pleiotropic biological effects, including a direct 
anti-tumor activity against several cancers. However, the precise 
mechanism of action of iPA in inhibiting cancer cell proliferation remains 
to be clarified. 
In this work, we investigated whether iPA could directly interfere with the 
angiogenic process, fundamental to cancer growth and progression, and if 
the growth and proliferation of human melanoma cells, known for their 
highly angiogenic phenotype, could be affected by the treatment with iPA. 
Finally, we investigated if iPA could have an immunomodulatory role 
targeting directly human natural killer (NK) cells, components of innate 
immunity that participate in immunity against neoplastic cells, in order to 
provide a cooperative and multifactorial mode of action of iPA to arrest 
cancer growth. To evaluate the potential involvement of iPA in 
angiogenesis, we employed human umbilical vein endothelial cells 
(HUVECs) as a suitable in vitro model of angiogenesis, by evaluating the 
viability, proliferation, migration, invasion, tube formation, and molecular 
mechanisms involved. Data were corroborated in mice by using a gel plug 
assay. iPA dose- and time-dependently inhibited all the neoangiogenesis 
stages, with an IC50 of 0.98 µM. We demonstrated for the first time that 
iPA was monophosphorylated into iPA 5'-monophosphate (iPAMP) by 
adenosine kinase (ADK) inside the cells. iPAMP is the active form that 
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inhibits angiogenesis through the direct activation of AMP-kinase 
(AMPK). Indeed, all effects were completely reversed by pre-treatment 
with 5-iodotubercidin (5-Itu), an ADK inhibitor. The isoprenoid 
intermediate isopentenyl pyrophosphate (IPP), which shares the 
isopentenyl moiety with iPA, was ineffective in the inhibition of 
angiogenesis, thus showing that the iPA structure is specific for the 
observed effects. Thus, iPA is a novel AMPK activator and could represent 
a useful tool for the treatment of diseases where excessive neoangiogenesis 
is the underlying pathology. 
The activation of AMPK seems to be the mechanism by which iPA exerts 
also its anticancer effects in A375 human melanoma cells. Indeed, in order 
to evaluate if iPA could be a useful agent able to inhibit tumor 
angiogenesis, we tested in vitro the ability of iPA to arrest the proliferation 
and the growth of melanoma, a tumor known for its highly angiogenic 
phenotype. In particular, we performed co-cultures of HUVEC and A375 
cells, and we evaluated melanoma cells vitality to delucidate their cell fate 
following iPA-treatment. Moreover, the molecular mechanism elicited by 
iPA in this cancer model was analyzed. According with endothelial cells, 
iPA (from 2.5 to 10 µM) was able to inhibit melanoma cell growth, 
inducing autophagy and subsequently apoptosis, through AMPK 
activation, acting as an AMP mimetic. 
In the last part of this work, we analyzed a possible role of iPA in immune 
regulation. In analogy to the unique specificity for phosphoantigens like 
IPP, shown by human Vγ9Vδ2 T cells, we report for the first time the 
ability of iPA to selectively expand and directly target human NK cells. 
Interestingly, at submicromolar concentrations, iPA stimulated resting 
human NK cells and synergized with IL-2 to induce a robust ex vivo 
activation with significant secretion of CCL5 and CCL3 and a large 
increase in TNF-α and IFN-γ production when compared with IL-2 single 
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cytokine treatment. Moreover, iPA was able to promote NK cell 
proliferation, upregulating the expression of specific NK cell activating 
receptors, as well as CD69 and CD107a expression. Cytotoxic activity of 
NK cells against tumor targets was due to a selective potent activation of 
MAPK signaling intermediaries downstream IL-2 receptor. The effect 
resulted at least in part from the fine modulation of the farnesyl 
diphosphate synthase (FDPS) activity, the same enzyme implicated in the 
stimulation of the human γδ T cells. The iPA-driven modulation of FDPS 
can cause an enhancement of post-translational prenylation essential for 
the biological activity of key proteins in NK signaling and effector 
functions, such as Ras. These unanticipated properties of iPA provide 
additional piece of evidence of the immunoregulatory role of the 
intermediates of the mevalonate pathway and open novel therapeutic 
perspectives for this molecule as an immune-modulatory drug.  
Taken together, these results highlight a sinergic mode of action of iPA as 
antitumor agent, interfering with neovascularization and hence blood 
supply to nourish cancer cells, inducing autophagy and apoptosis directly 










1.1 N6-isopentenyladenosine, an endogenous isoprenoid end-
product, from plants.. 
N6-isopentenyladenosine (iPA) is a modified adenosine characterized by 




Figure 1. Chemical structure of iPA 
 
iPA belongs to a class of substances known as cytokinins, which are 
important purine derivatives that serve as hormones that control many 
processes in plants (Bifulco et al., 2008). Cytokinin literally means 
stimulus of cell movement (cytokinesis) but it is also used in terms of cell 
division. They were discovered as factors promoting cell division in 
tobacco tissue cultures (Skoog et al., 1965) and have been shown to 
regulate several other developmental events, such as de novo bud 
formation, release of buds from apical dominance, leaf expansion, delay of 
senescence, promotion of seed germination, and chloroplast formation 
(Mok and Mok, 2001). Thus, cytokinins are plant growth regulators 
defined by their ability to promote cell division in tissue cultured in 
presence of auxin (Astot et al., 2000). The discovery of auxin, the first 
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organic substance defined as hormone of the plants, led to the discovery of 
other chemical substances regulating the plant growth. As in the animal 
world, it was unlikely that plant growth and development depended on the 
control of a unique hormone. Indeed, it was found a growth factor derived 
from DNA degradation that stimulated the growth of plant tissues in vitro 
(Skoog et al., 1965). This substance was named kinetin and the class of 
regulators was named cytokinins. The general term “kinin” was created to 
describe chemicals that promote cell division, but it was subsequently 
replaced by “cytokinin” for confusion with the term kinin from the realm 
of zoology (Oka, 2003). In 1963 the first cytokinin in plants was 
discovered from the immature cariosside of corn (Zea mais): the substance 
was named zeatin (Oka, 2003). iPA is one of the cytokinins isolated from 
plants and its ribosides, ribotide and 2- methyltioderivate are known 
(Bifulco et al., 2008). Many studies suggest that cytokinins are mainly 
generated in the radical system and transported to the aerial part through 
the xilematic flux. The metabolism of cytokinins seems to occur in various 
tissues of the plant, either by elimination of the side chain through 
cytokinins oxidases or by ribosylation. Glucosylation seems to occur in the 
leaves: glucosides could store hormones which, when required, are 
transported in specific organs. All the known cytokinins present adenine 
substitution on position N6, with an isoprenoid or an aromatic group 
(Bifulco et al., 2008). 
 
1.2 ..to mammals 
iPA was found in transfer RNA (tRNA) of many eukaryotic and 
prokaryotic cells (Burns et al., 1976) and it is the only known cytokinin 
existing in animal tRNAs, specifically at position 37 of the tRNA 
molecules that bind codons starting with uridine (Persson et al., 1994). It is 
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a rare component of some ribosomal RNA and was isolated from yeast 
through the hydrolysis of the serine of tRNA. Free iPA, not linked to 
tRNA, was found in cell extracts of Saccharomyces cerevisiae and 
Schizosaccharomyces pombe (Laten and Zahareas-Doktor, 1985). 
However, the cell levels of free iPA are not decreased in yeast strains 
having mutations that result in reduced amounts of isopentenylated tRNA 
(Faust and Dice, 1991). This result demonstrates that free iPA is derived 
from a biosynthetic pathway independent from isopentenyl tRNA 
degradation and probably related to modifications of monophosphate 
adenosine. 
The adenosine is generated through the classic biosynthetic pathway of 
nucleosides, while the isoprenoid chain derives from a product of the 
mevalonate pathway and, more specifically, from dimethylallyl 
pyrophosphate (DMAPP), which is in equilibrium with its isomer 
isopentenyl pyrophosphate (IPP) (Faust and Dice, 1991). iPA is typically 
found next to the 3' of the tRNA anticodon that binds to codons containing 











site suggests a role in the process of transduction. The tRNA containing 
iPA binds more efficiently the ribosome than the unmodified analogous 
nucleoside, thus demonstrating that the absence of isopentenyladenosine 
decreases the efficacy of transduction in vitro and in vivo (Warner et al., 
2000; Moustafa et al., 2001; Bifulco et al., 2008).  
It was previously believed that the RNA degradation was the main source 
of free cytokinins, including iPA. Nevertheless, calculation on the rate of 
RNA turnover demonstrated that a de novo biosynthetic pathway 
independent from tRNA should be present in plants; a further step was the 
discovery of an enzyme for cytokinin biosynthesis in Dictiostelum 
discoideum. Cell extracts from this organism can convert adenosine 5'-
monophosphate (AMP) and DMAPP in cytokinins: N6-
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isopentenyladenosine-5'-monophosphate (iPAMP) and the correspondent 
nucleoside iPA (Fig. 2). Moreover, in 1984 it was shown that the product 
of the T-DNA gene4 (ipt) of the crown gall-forming bacterium, 
Agrobacterium tumefacien, was an isopentenyl transferase, IPT (Bifulco et 
al., 2008). IPTs are a family of enzymes, conserved from microorganisms 
to mammals, that catalyze the addition of iPA on residue 37 of tRNA 
molecules using DMAPP as donor of the isopentenyl group. IPT is also 
involved in the synthetic pathway independent of isopentenylated tRNA 
degradation (Golovko et al., 2000; Spinola et al., 2005). 
 
Figure 2. Proposed biosynthesis of iPA in plants 
 
Astot and coworkers provided then evidence for an alternative iPAMP 
independent cytokinin biosynthetic pathway both in Arabidopsis thaliana 
expressing the Arabidopsis tumefaciens ipt gene and as part of normal 
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wild-type plant metabolism (Astot et al., 2000). Sequence analysis shows 
the homology between the human and Saccharomyces cerevisiae and 
Escherichia coli IPT aminoacid sequence. All well-conserved motifs 
present in tRNA-IPT can be found in the deduced human protein sequence 
(Golovko et al., 2000). The full-length TRIT1 transcript is able to 
complement the yeast tRNA-IPT biochemical activity, producing amounts 
of iPA-tRNA similar to those produced by the yeast gene. In mammalian 
cells, iPA is found in selenocysteine (Sec) tRNA that decodes UGA stop 
codons and inserts Sec residues into nascent peptides. The ability to decode 
UGA as a Sec codon is affected when the tRNA
Sec
 lacks iPA at position 37 
as demonstrated in Xenopus (Spinola et al., 2005). iPA is therefore the only 
cytokinin modified tRNA species found in animals. However, biosynthesis 
of iPA in mammals has not been fully disclosed. 
 
1.3 Biological effects of N6-isopentenyladenosine 
It has been proved that in plants cytokinins are able to induce callus 
(clusters of dedifferentiated plant cells that proliferate indefinitely in a 
disorganized manner) to re-differentiate into adventitious buds, just like 
human cancer cells. Because of these similarities, cytokinins may also 
affect the differentiation of human cancer cells through mechanisms of 
action that could involve common signal events of the signal transduction 
(Bifulco et al., 2008). Indeed, whilst iPA biosynthesis in mammals has not 
been fully disclosed, some of its biological effects are known, including 
anti-tumour action on human and murine cells. 
More than forty years ago, it has been shown by Gallo and colleagues that 
iPA can exert a promoting or inhibitory effect on human cell growth, on 
the bases of used concentration and the cell cycle phase. They reported a 
biphasic effect of iPA: an inhibitory action at high μM concentrations and 
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a stimulatory effect at lower concentrations (0.1-1.0 μM). Moreover, they 
demonstrated that the addition of iPA 12 hours after phytohemagglutinin 
stimulation determined a decrease of mitotic figures, suggesting that iPA 
effects depend on the phase of cell cycle. It was also demonstrated that the 
effects on DNA synthesis are preceded by the inhibition of RNA and 
protein synthesis. The mechanism of RNA inhibition could be the result of 
the competition of iPA with the adenosine-3'-phosphate, adenosine or 2'- 
deoxyadenosine 5'-triphosphate during RNA synthesis. However, the 
addition of such substances, even at higher concentrations of iPA, did not 
decrease its inhibitory effect (Gallo et al., 1969). Inhibitory effect of iPA 
has been demonstrated also on the growth of sarcoma cells at very high 
concentration (22 and 100 μM). Studies from these cell extracts 
demonstrated in silico that iPA may be a potential substrate for adenosine 
kinase, and also a weak inhibitor of adenosine deaminase, glucose-6-
phosphate-dehydrogenase and methylase of mammalian tRNAs. iPA acts 
also as potent inhibitor of the uptake of purine and pirimidine nucleosides. 
The authors suggest that iPA cytotoxicity for these cells might be due to its 
conversion in 5'-monophosphate even if they don’t definitively prove it. 
This derivative molecule from iPA, at high intracellular levels, could be 
cytotoxic since it affects the enzymes involved in purine metabolism 
(Divekar et al., 1973). 
More recent studies demonstrated that iPA exerts a significant apoptotic 
effect on viable human lymphocytes. The capacity of the modified 
ribonucleosides to induce apoptosis was studied also in several human cell 
lines and it was observed that iPA was the most active cytokinin. The 
cancer cell lines Caco-2 and HL-60 were more reactive to an apoptotic 
stimulation than non-malignant human peripheral blood lymphocytes 
(Meisel et al., 1998). In a thyroid cell system iPA was able to influence 
cAMP dependent organization of the microfilaments. The effects of iPA 
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were exerted both on the synthesis of cAMP and on its activity, probably 
due to the substitution on the nitrogen 6 of adenosine (Laezza et al., 1997). 
Of note, iPA is the only adenosine substituted on nitrogen 6 with 
physiologic relevance. Then, the same research group investigated the anti-
proliferative effect of iPA, highlighting a dose-dependent arrest of the G1 
cell phase transition associated with a reduction of cells in the S phase 
through the inhibition of farnesyl diphosphate synthase (FDPS) and protein 
prenylation. Interestingly, iPA effect was not mediated by the adenosine 
receptors but was due to a direct modulation of FDPS enzyme activity as a 
result of its uptake inside the cells (Laezza et al., 2006). The 
antiproliferative activity of iPA was confirmed also in 9 human epithelial 
cancer cell lines derived from different types of malignant tissues (Spinola 
et al., 2007): it was observed a complete suppression of clonogenic activity 
in 8 of the cell lines after exposure to iPA at a concentration of 10 μM. The 
observed effects appeared to reflect a block in DNA synthesis, not 
involving a FDPS down-regulation in lung cells model. These findings are 
consistent with the reported inhibition of proliferation of rat thyroid tumor 
cells induced by iPA. Although iPA has been reported to induce apoptosis 
as well as differentiation in a human myeloid leukemia cell line (Ishii et 
al., 2002), any pro-apoptotic effect has been reported in thyroid and 
epithelial cancer cells (Laezza et al., 2006; Spinola et al., 2007). Moreover, 
iPA was able to cause a pronounced change in cell morphology, associated 
to a disorganization of actin fibers in the cytoplasm, suggestive of a cell 
stress condition. Antiproliferative effects of iPA was confirmed also on 
human colon cancer cells, through inhibition of DNA synthesis and 
induction of apoptosis (Laezza et al., 2009). 
There are some evidence of the activity of iPA also in patients. A far away 
work described a clinical study on the therapeutic use of iPA on twenty 
leukaemia patients who were treated daily with intravenous infusion of 
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iPA. Patients received the substance drug orally or intravenous, showing 
transient and short lasting effects of the therapy probably due to iPA 
instability (Mittelman et al., 1975). Other researchers had already reported 
that iPA inhibited the growth of various cancers, but iPA LD50 was 
different and dependent on the way of administration and species (from ca. 
200 to 800 mg/Kg). However, they focused particularly on toxic effects 
(hepatotoxicity, pancreatic atrophy and antiproliferative effects in 
lymphoid tissue) of iPA in rats and dogs and did not gain further insights 
into the observed antitumour effects (Suk et al., 1970). 
No additional example of in vivo anticancer activity has been reported for 
humans or, in general, mammalians up to the present. Only in 2006, the 
successful inhibition of a rat tumour by iPA injected in a nude mouse 
directly at the tumour site has been reported, without detectable toxic or 
hypolocomotor effects on the treated animals (Laezza et al., 2006). Later, 
Colombo and colleagues have shown no significant in vivo activity of iPA 
injected intraperitoneally into nude mice inoculated with ovarian-
carcinoma cells, suggesting that the pharmacokinetics of the compound do 
not allow to reach efficacious concentrations. The lack of activity might 
rest in the rapid clearance and short half-life in vivo of circulating 
nucleosides and, most likely, of circulating iPA (Colombo et al., 2009). 
Taken together, these data suggest that this isoprenoid end product might 
be used for antineoplastic therapy, representing a potential new anticancer 
drug. However, it would be necessary to increase knowledge about the 
exact biological role of iPA inside mammalian cells even in the sense of its 
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1.4 Basic aspects of angiogenesis 
The term ‘‘angiogenesis’’ is commonly used to reference the development 
of new blood vessels growth from preexisting vasculature. It plays an 
important role in physiologic conditions, including development, 
reproduction, wound healing and bone morphogenesis, and in pathologic 
ones as cancer, intraocular neovascular disorders, rheumatoid arthritis, 
psoriasis and others. The entire process, that consists in localized 
enzymatic degradation of basal membrane, migration and proliferation of 
endothelial cells, and lumen formation of the new capillary (Fig. 3), is 
finely controlled by a tuned balance between positive and negative 
effectors (Carmeliet, 2003). In the embryo, new vessels form de novo via 
the assembly of mesoderm-derived endothelial precursors (angioblasts) 
that differentiate into a primitive vascular labyrinth (vasculogenesis) (Swift 
and Weinstein, 2009). Subsequent vessel sprouting (angiogenesis) creates a 
network that finally remodels into arteries and veins (Adams and Alitalo, 
2007). Recruitment of pericytes and vascular smooth muscle cells that 
enwrap nascent endothelial cell tubules provides stability and regulates 
perfusion (arteriogenesis) (Jain, 2003). In the adult, vessels are quiescent 
and rarely form new branches. 
Vessels can also grow through other mechanisms, such as the splitting of 
pre-existing vessels through intussusception or the stimulation of vessel 
expansion by circulating precursor cells (Fang and Salven, 2011; Makanya 
et al., 2009). 
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Figure 3. The cellular steps involved in angiogenesis 
 
Blood vessels supply oxygen and nutrients and provide gateways for 
immune surveillance. As this network nourishes all tissues, it is not 
surprising that structural or functional vessel abnormalities contribute to 
many diseases. Inadequate vessel maintenance or growth causes ischemia 
in diseases such as myocardial infarction, stroke, and neurodegenerative or 
obesity-associated disorders, whereas excessive vascular growth or 
abnormal remodeling promotes many ailments including cancer as routes 
for tumor cells to metastasize, inflammatory disorders, and eye diseases 
(Carmeliet, 2003; Folkman, 2007). 
 
1.5 Angiogenesis in cancer 
Angiogenesis is widely considered as an essential process to nourish the 
growing tumor and to remove metabolic waste products (Folkman, 1971). 
Intratumoral hypoxia leads to the stabilization and expression of the pro-
tumorigenic hypoxia-inducible factor (Hif)α transcription factors. Under 
Chapter 1  BACKGROUND 
11 
normal oxygen levels, Hif-1α and Hif-2α are short-lived because prolyl 
hydroxylase (PHD) proteins mediate their degradation (Fong and Takeda, 
2008). During hypoxia, PHD proteins show reduced activity, which results 
in the formation of heterodimerization by Hif-1α and Hif-2α with Hif-1β. 
This complex is able to trigger the expression of genes containing hypoxia-
responsive elements, including the gene encoding vascular endothelial 
growth factor (VEGF) (Qing and Simon, 2009). Under hypoxic conditions, 
pericytes are able to secrete VEGF which can act in a paracrine manner on 
endothelial cell proliferation (Reynolds et al., 2000). In consequence, the 
quiescent vascular network is getting disturbed and activated (Fig. 4). 
 
 
Figure 4. Tumor associated-angiogenesis 
 
Whereas blood vessel growth is tightly controlled under physiological 
conditions, tumor progression is highly associated with the acquisition of 
an angiogenic phenotype based on a transition from the avascular to the 
vascular phase (Folkman et al., 1989). This process is called the 
“angiogenic switch”, in which the balance of pro- and anti-angiogenic 
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molecules leads toward angiogenic inducers (Folkman and Hanahan, 
1991). Tumor vasculature is often characterized by the presence of poorly 
developed so called “immature” vessels with multiple branch-points and 
deregulated vessel sprouting which contributes to tumor hypoxia. In 
particular, tumor vessels display abnormal structure and function with 
seemingly chaotic organization. Endothelial cells lack a cobblestone 
appearance, are poorly interconnected and occasionally multilayered. Also, 
arterio-venous identity is ill defined and shunting compromises flow. The 
basement membrane is irregular in thickness and composition, and fewer, 
more loosely attached hypocontractile mural cells cover tumor vessels, 
though tumor-type-specific differences exist. The resulting irregular 
perfusion impairs oxygen, nutrient and drug delivery (Goel et al., 2011). 
Neovascularization enhances tumor cell proliferation, local invasion and 
hematogenous metastasis. However, the abnormalities of tumor vessels 
provide the potential for targeting these vessels without destroying the 
normal vasculature (Arap et al., 2002). 
Vessel leakiness, together with growing tumor mass, increases the 
interstitial pressure and thereby impedes nutrient and drug distribution. The 
loosely assembled vessel wall also facilitates tumor cell intravasation and 
dissemination. As a consequence of poor oxygen, nutrient and growth 
factor supply, tumor cells further stimulate angiogenesis in an effort to 
compensate for the poor functioning of the existing ones. However, this 
excess of proangiogenic molecules only leads to additional disorganization 
as the angiogenic burst is nonproductive, further aggravating tumor 
hypoperfusion in a vicious cycle. 
Nowadays anti-angiogenetic pharmacological approaches are approved for 
several advanced metastatic cancers, in combination with validated 
chemotherapy or cytokine therapy, aimed at blocking vessel growth 
targeting VEGF (Potente at al., 2011). The hypoxic and acidic tumor 
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milieu constitutes a hostile microenvironment that is believed to drive 
selection of more malignant tumor cell clones and further promotes tumor 
cell dissemination. The uneven delivery of chemotherapeutics, together 
with a reduced efficacy of radiotherapy owing to the lower intratumoral 
oxygen levels, limit the success of conventional anticancer treatments. 
Moreover, tumors would be able to switch mechanisms of vascular growth 
and some of these mechanisms rely less on VEGF, so they would possess 
the means to escape from treatment with VEGF receptor inhibitors. 
Identifying the molecular basis of these alternative modes of vessel growth 
will thus be critical to improve the efficacy of antiangiogenic treatment 
(Potente et al., 2011). 
Despite efforts to stimulate angiogenesis therapeutically by proangiogenic 
factors, most trials failed to meet these expectations. Alternative strategies, 
based on pro-angiogenic cell therapies or targeting of microRNAs, offer 
new opportunities but are in (pre)clinical development (Bonauer et al., 
2010). Nonetheless, only a fraction of cancer patients show benefit as 
tumors evolve mechanisms of resistance or are refractory toward VEGF 
receptor inhibitors. Conflicting results about the benefit of VEGF blockade 
have kick-started a debate on whether antiangiogenic treatment may trigger 
more invasive and metastatic tumors. On the upside, ‘‘sustained 
normalization’’ of abnormal tumor vessels may offer benefit for fighting 
metastasis (Goel et al., 2011). 
 
1.6 A snapshot of melanoma 
Melanoma is a cutaneous tumor characterized by abnormal proliferation of 
melanocytes that invade the basement membrane. Recent epidemiologic 
evidence has documented both an increase in incidence of and in mortality 
from malignant melanoma. The importance of this relatively uncommon 
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malignant neoplasm (incidence less than 5/100,000 population) is attested 
to the fact that despite accounting for only 3% of all cutaneous malignant 
neoplasms, malignant melanoma causes 67% of the deaths attributable to 
skin cancer (Cummins et al., 2006). Malignant melanoma has a poor 
prognosis and limited therapeutic options, particularly in advanced tumors. 
The 5-year-survival rate of advanced tumors with distant metastases is still 
as low as 5-10% (Balch et al., 2009). Surgical resection of the primary 
tumour offers a significant chance of cure and remains the mainstay of 
treatment where possible. However, melanoma, which can progress to a 
stage of spreading with low invasive potential (radial growth phase) to the 
next stage (vertical growth phase), disseminates early, both intradermally 
and through lymphatic and haematogenous routes and therefore despite 
resection, once there is invasion into the dermis of the skin, the outlook 
changes dramatically. 
Chemotherapy with the alkylating agent dacarbazine as monotherapy was 
established as treatment for metastatic melanoma thirty years ago and 
remains the standard of care outside of clinical trials. However the 
response rate of melanoma to dacarbazine is only in the region of 15 to 
20% and it has not been shown to improve overall survival. Therefore, 
there is an urgent need to find more effective treatments for this condition 
(Zaki et al., 2012). An area of significant interest for modern cancer 
therapeutic strategies is targeting angiogenesis, as this is one of the 
cardinal patho-physiological features of invasive cancer, essential for 
tumour growth and metastasis (Hanahan and Weinberg, 2000). Indeed, 
melanoma is well-recognised to be a highly vascular tumour. However the 
impact on tumor-induced angiogenesis for disease progression and 
metastasis remains controversial (Helfrich and Schadendorf, 2011). 
Anyway, it is well known that the overproduction of VEGF165 and its 
association with VEGF receptor (VEGFR) expression promotes melanoma 
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cell growth and survival through MAP kinase and phosphatidyl inositol-3-
kinase (PI3K) signaling pathways (Graells et al., 2004). Moreover, 
immunohistochemical studies suggest that VEGF is expressed by 20–77% 
of human primary melanomas. VEGF also increased during follow-up 
(Zaki et al., 2012). Expression of VEGF, VEGF-R1, VEGF-R2 and VEGF-
R3 was observed to be significantly higher in malignant melanocytes when 
compared with samples from their benign counterparts, supporting the 
hypothesis that in particular the upregulation of VEGF-R2 may select for 
an angiogenic phenotype. Clinically, the expression and activation of 
MMPs is related to the degree of invasiveness and metastasis of melanoma 
and also correlates with low survival rates in melanoma patients (Hofmann 
et al., 2000). In summary, it is clear that angiogenesis represents a relevant 
process to target in melanoma. There is therefore a strong biological 
rationale to incorporate the anti-angiogenic strategy into therapeutic plans. 
Whereas cytotoxic chemotherapy targets DNA repair and the cell cycle to 
induce cell killing through apoptosis, antiangiogenic therapy is more 
cytostatic. The main targets are: pro-angiogenic ligands; kinases that are 
intrinsic to extracellular endothelial cell receptors or growth factor 
pathways essential for survival and proliferation within endothelial cells; 
MMPs and integrins. Agents used in these anti-angiogenic strategies may 
be further sub-divided according to their chemical entity in monoclonal 
antibodies (mAbs), small molecule kinase inhibitors that abrogate receptor 
or cytoplasmic kinases and VEGF-trap, that is a composite decoy receptor 
based onVEGFRs, fused to an Fc segment of IgG1 (Holash et al., 2002). 
Early phase trials suggest clinical activity using a variety of anti-
angiogenic drugs, but the data are as yet too immature to provide 
conclusive evidence of clinical benefit in melanoma patients. Given the 
existence of redundant pathways that may compensate for inhibition of a 
single angiogenic axis, it is highly unlikely that targeting a single pathway 
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will be sufficient to achieve optimal tumor control in melanoma. Therefore 
there are ongoing questions over whether targeting multiple ligands, 
receptors or kinases within several signaling pathways may be 
advantageous over specific inhibition of single targets. 
 
1.7 AMP-activated protein kinase, sensor of cellular energy 
AMP-activated protein kinase (AMPK) is a highly conserved sensor of 
cellular energy status that exists in the form of heterotrimeric complexes 
containing a catalytic α-subunit combined with regulatory β- and γ- 
subunits (Hardie et al., 2012). Metabolic stress caused by nutrient 
deprivation, prolonged exercise, ischemia or hypoxia mediates the 
activation of AMPK, initiating a cellular program to conserve energy by 
turning on ATP-generating catabolic pathways and switching off ATP-
consuming anabolic pathways through direct phosphorylation of target 
proteins and modulation of gene expression (Hardie et al., 2006). Changes 
in the AMP- or ADP/ATP ratio, alterations in intracellular calcium 
concentrations as well as AMP mimetics cause AMPK activation. 
Recently, in addition to AMPK role in energy homeostasis, emerging 
evidence indicates that AMPK regulates endothelial cell function, 
modulating vascular tone by activation of endothelial nitric oxide synthase 
(eNOS) (Morrow et al., 2003). Moreover, AMPK exerts important anti-
inflammatory effects by blocking the expression of adhesion molecules 
and chemokines by endothelial cells (Ewart et al., 2008). Significantly, 
many of the beneficial actions of AMPK on endothelial cell function are 
related to the activation of eNOS or the induction of the vasoprotective 
protein heme oxygenase HO-1 (Liu et al., 2011). Although the ability of 
AMPK to preserve endothelial cell viability is well appreciated, the role of 
AMPK in regulating endothelial cell proliferation is limited and not well 
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understood (Reihill et al., 2011). AMPK activation is related with 
inhibition of endothelial cells proliferation and migration (Peyton et al., 
2012) or with decreased angiogenesis and inhibition of macrophage 
infiltration associated to the inhibition of retinoblastoma proliferation in 
vivo (Theodoropoulou et al., 2013). 
Although AMPK has not yet been formally demonstrated to be a tumour 
suppressor, there are many indications that this is the case: AMPK 
activation inhibits cell growth and proliferation; AMPK exerts many 
effects of LKB1, a known tumour suppressor; AMPK up-regulates 
oxidative metabolism and would therefore be expected to mediate an ‘anti- 
Warburg’ effect; and similar to other known tumour suppressors, AMPK 
activation is down-regulated in many tumour cells, by loss of LKB1 and 
other mechanisms (Dandapani and Hardie, 2013). These considerations led 
to studies investigating whether the use of AMPK-activating drugs in 
humans might affect the incidence of cancer. Indeed, Type 2 diabetics 
taking the AMPK-activating drug metformin have significantly reduced the 
incidence of cancer compared with those on other medications (Decensi et 
al., 2010). The nucleotide ZMP, also referred as AICAR (5-amino-4-
imidazolecarboxamide 1-β-Dribofuranoside) monophosphate, is an 
intermediate in purine nucleotide synthesis, but also acts as an AMP 
mimetic that mimics all of the effects of AMP on the AMPK system 
(Corton et al., 1995). Incubation of most cells with the equivalent riboside 
(AICAR) causes accumulation of ZMP, because its uptake and 
phosphorylation to ZMP is rapid compared with subsequent metabolism; it 
has therefore been widely used to activate AMPK in intact cells and in 
vivo. Recently, some reports have implicated AMPK in the regulation of 
autophagy. The activation of AMPK leads to the suppression of 
mammalian target of rapamycin (mTOR), thereby activating autophagy 
(see below) (Wang et al., 2011). 
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1.8 Double face of autophagy: promoter of cell survival or cell 
death? 
The word autophagy is derived from the Greek roots “auto” (self) and 
“phagy” (eating) and broadly refers to the cellular catabolic processes in 
which cytoplasmic materials are transported to lysosomes for degradation. 
Christian de Duve, who was awarded the Nobel Prize for his work on 
lysosomes, first used the term autophagy in 1963 (Wang and Qin, 2013). 
There are several different types of autophagy: macroautophagy, 
microautophagy and chaperone-mediated autophagy (Fig. 5). 
Macroautophagy (hereafter referred to as autophagy) is the main route for 
the sequestration of cytoplasm into the lytic compartment. 
 
 
Figure 5. Three main forms of autophagy 
 
Autophagy is a lysosomal pathway involved in the turnover of cellular 
macromolecules and organelles. The first step of autophagy is the 
envelopment of cytosol and/or organelles in the isolating membrane, which 
wraps around the cargo forming an autophagosome, a vesicle surrounded 
by a double membrane. Autophagosome then undergoes a progressive 
maturation by fusion with endolysosomal vesicles creating an 
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autolysosome, where the cargo is degraded. Autophagy is controlled by a 
set of evolutionarily conserved autophagy-related proteins (Atg proteins). 
The initial nucleation and assembly of the primary autophagosomal 
membrane requires a kinase complex that consists of class III 
phosphatidylinositol 3-kinase (PI3K), p150 myristylated protein kinase and 
beclin 1 (also known as Atg6). The further elongation of the isolation 
membrane is mediated by two ubiquitin-like conjugation systems one of 
them resulting in the conversion of microtubule-associated protein 1 light 
chain 3 (LC3; also know as Atg8) from free form (LC3-I) to a lipid-
conjugated membrane-bound form (LC3-II) (Fig. 6). The accumulation of 
LC3-II and its localization to vesicular structures are commonly used as 
markers of autophagy (Høyer-Hansen and Jäättelä, 2007). Autophagy in 
mammalian systems occurs under basal condition and can be stimulated by 
stress, including starvation, oxidative stress, or by treatment with the 
pharmacological agent rapamycin. In addition to its roles in maintaining 
normal cellular homeostasis by liberating nutrients from macromolecules 
and by assisting the clearance of misfolded proteins and damaged 
organelles, autophagy plays a role in the destruction of some bacteria 
within the cells. 
Autophagy is also involved in removing damaged or excess organelles. For 
example, mitochondria that have lost their membrane potential and 
peroxisomes in response to changing environmental cues can be selectively 
removed by autophagy (Rodriguez-Enriquez et al., 2004). Endoplasmic 
reticulum (ER) stress caused by the accumulation of unfolded proteins 
threatens cell survival and triggers the evolutionarily conserved ER to 
nucleus signaling pathway called the unfolded protein response (UPR), 
which reduces global protein synthesis and induces the synthesis of 
chaperones and other proteins that increase the capacity of the ER to fold 
its client proteins. When the ER stress is extensive or sustained, and the 
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function of ER cannot be restored, it leads to the removal of the affected 
cells by apoptosis. Accumulating data now indicate that ER stress is also a 
potent trigger of autophagy (Høyer-Hansen and Jäättelä, 2007). Whereas 
the induction of autophagy by ER stress is conserved from yeast to 
mammals, the signaling pathways responsible for autophagy induction and 
its cellular consequences appear to vary according to the cell type and the 
stimulus. A better understanding of the signaling pathways controlling 
autophagy and the cellular fate in response to ER stress will hopefully open 
new possibilities for the treatment of the numerous diseases related to ER 
stress. In addition to activating the UPR by the pathways discussed above, 
ER-stress leads to a release of calcium from the ER into the cytosol, which, 
in turn, can activate various kinases and proteases potentially involved in 
autophagy signaling, as AMPK. It is not clear whether activation of AMPK 
is enough to trigger autophagy or whether other independent signals are 
required in parallel. The data presented above encourage the development 
of autophagy promoting therapies for diseases associated with protein 
aggregates either in the ER or the cytosol. If this proves to be the case, 
combination therapies with ER stressors and autophagy inhibitors may 
prove useful in cancer therapy. The direct link between ER stress and 
autophagy was reported recently. Thus, it is natural that many burning 
questions concerning the signaling pathways linking ER stress to 
autophagy, the mechanisms by which ER is selected as autophagic cargo, 
the crosstalk between ER stress-induced autophagy and cell death 
pathways, and the impact of autophagy in diseases associated with ER 
stress remain largely unanswered. The future research will hopefully 
clarify these points and pave the way for pharmacological exploitation of 
the signaling pathways involved (Høyer-Hansen and Jäättelä, 2007). 
It has also been proposed that autophagy results in the total destruction of 
cells. Autophagic cell death represents one of several types of programmed 
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cell death. Autophagy is vital in a range of physiological and pathological 
situations, including cell growth, aging, cell death and clearing pathogenic 
bacteria (Rami, 2009). This mechanism provides an internal source of 
nutrients for energy generation and survival. When the supply of nutrients 
is limited, stimulating autophagy contributes to the lysosomal recycling of 
nutrients to maintain protein synthesis and glucose synthesis from amino 
acids and to form substrates for oxidation and ATP production in the 
mitochondria and the inhibition of the default apoptotic pathway. 
Moreover, starvation-induced autophagy is cytoprotective by blocking the 
induction of apoptosis upstream of mitochondrial events. Some metabolic 
changes (ATP levels, amino acids, and insulin) may regulate autophagy. 
AMPK is a crucial cellular energy sensor. Once activated by falling energy 
status, it promotes ATP production by increasing the activity or expression 
of proteins involved in catabolism while conserving ATP by switching off 
biosynthetic pathways (Hardie et al., 2012). The AMPK pathway appears 
to be involved in autophagy induced by nutrient deprivation, growth factor 
withdrawal and hypoxia. The activation of AMPK leads to the suppression 
of mammalian target of rapamycin (mTOR), thereby activating autophagy. 
Under nutrient-rich conditions, ER-associated Bcl-2 and Beclin 1 interact 
to sequester Beclin 1 from the autophagy complex (Wang and Qin, 2013). 
This association is broken by starvation and is triggered by Bcl-2 
phosphorylation by JNK1. Recruitment of the Beclin 1-PI3-kinase 
complex to the autophagic membrane is also dependent on the ULK1 
complex. 
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Figure 6. Schematic depiction of autophagy. Mammalian autophagy is initiated by the 
formation of the phagophore, followed by a series of steps, including the elongation and 
expansion of the phagophore, closure and completion of a double-membrane 
autophagosome (which surrounds a portion of the cytoplasm), autophagosome maturation 
through docking and fusion with an endosome (the product of fusion is known as an 
amphisome) and/or lysosome (the product of fusion is known as an autolysosome), 
breakdown and degradation of the autophagosome inner membrane and cargo through 
acid hydrolases inside the autolysosome, and recycling of the resulting macromolecules 
through permeases. The core molecular machinery is also depicted, such as the ULK1 and 
ULK2 complexes that are required for autophagy induction, class III PI3K complexes that 
are involved in autophagosome formation, mammalian Atg9 (mAtg9) that potentially 
contributes to the delivery of membrane to the forming autophagosome and two 
conjugation systems, the LC3-II and Atg12–Atg5–Atg16L complex, which are proposed 
to function during elongation and expansion of the phagophore membrane. 
This biosynthetic pathway may be an attractive target for cancer treatment 
(Wang and Qin, 2013). Autophagy is a cell survival mechanism that 
involves the degradation and recycling of cytoplasmic components. In 
addition, autophagy mediates cell death under specific circumstances. 
Autophagic cell death (type II cell death) and apoptosis (type I cell death) 
have taken center stage as the principal mechanisms of programmed cell 
death in mammalian tissues. Although autophagy and apoptosis are 
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markedly different processes, autophagy and apoptosis can act as partners 
to induce cell death in a coordinated or cooperative fashion. Several 
signaling pathways that are induced by common cellular stressors regulate 
both autophagy and apoptosis. For example, Bcl-2 phosphorylation may 
not only be a mechanism for regulating apoptosis and a mechanism for 
regulating autophagy, but may also be a mechanism for regulating the 
switch between the two pathways. It is suggested that Bcl-2 also plays an 
essential role in limiting autophagy activation and preventing the initiation 
of programmed cell death (Zhang et al., 2009). The tumor suppressor p53 
regulates both autophagy and apoptosis. Among other mechanisms, p53 
can initiate apoptosis by inducing the expression of p53-upregulated 
modulator of apoptosis (PUMA), which leads to the release of cytochrome 
c from mitochondria and apoptotic cell death. In addition, p53 affects 
autophagy by modulating signaling through the mTOR nutrient-sensing 
kinase, which controls autophagy at the initiation stage. Autophagy 
proteins can play a role in cellular events that occur during apoptosis. For 
example, Atg5 may be a point of crosstalk between autophagic and 
apoptotic pathways (Wang and Qin, 2013). On the other hand, autophagy 
is emerging as a built-in mechanism that malignant cells can exploit for 
protection against a variety of intrinsic and extrinsic stress signals. 
However, excessive or derailed autophagy can also favor cell death. How 
these two seemingly opposing roles of autophagy can have an impact upon 
cancer chemoresistance remains unclear (Wang and Qin, 2013). 
 
1.9 Immune regulation in cancer: focus on melanoma 
Immune responses to cancer can be readily demonstrated, which indicates 
that immune-surveillance plays a role in control of tumor development. 
However, tumors growing under immune pressure might develop various 
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mechanisms to evade immune recognition; a process generally known as 
immune-evasion. Two key processes that counter immune-surveillance are 
immune-subversion, in which tumor cells or the tumor microenvironment 
suppresses the immune response, and immune-editing, which refers to the 
role of the immune response in selecting tumor variants that have become 
poorly immunogenic, thus allowing for their outgrowth. One mechanism 
that can have opposing outcomes on subset of innate effector cells, 
cytotoxic T lymphocytes (CTLs) and natural killer (NK), is the loss or 
downregulation of HLA class I molecules. Metastatic melanoma is the 
most lethal form of skin cancer despite its immunogenicity (Tsao et al., 
2004). Indeed, melanoma antigens do elicit T cell responses, but T cell-
based immunotherapies have shown limited success (Carrega et al., 2009). 
Although potent T cell responses are desirable, the downregulation of HLA 
class I on melanoma cells might play a significant role in the pathogenesis 
and clinical course of the disease, and it represents a considerable problem 
for T cell-based immunotherapy. Therefore, new strategies are required. 
Belonging to innate immunity, NK cells are cytolytic lymphocytes that can 
directly kill transformed and microbe-infected cells. Moreover besides 
their ability to kill aberrant cells, NK cells have the capacity to produce a 
variety of cytokines and chemokines (TNF-α, IFN-γ, CCL3, CCL5, IL-8, 
IL-10 etc), through which they also participate in the shaping of adaptive 
immune response (Vivier et al., 2009). These NK cell effector functions 
are regulated by multiple activating and inhibitory NK cell receptors 
(Lanier, 2005). Engagement of activating receptors, such as natural 
cytotoxicity receptors (NCRs; NKp30, NKp44, and NKp46) and NKG2D, 
leads to the activation of a variety of downstream signaling molecules, 
which result in the activation of MAPKs, particularly ERK, which are 
crucial for cytolytic granule release and cytokine generation (Vivier et al., 
2004). 
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Despite the prevailing view that immunological surveillance is triggered by 
danger signals, signals that arise from injured cells, toxins, pathogens and 
mechanical damage, a recent work has shown that locally resident immune 
cells in the skin can detect early signs of cellular stress, through the 
recognition of ligands on premalignant cells and thus overt tumor 
transformation (Strid et al., 2008). NK cells reside in the skin (Luci et al., 
2009), thus melanocytes are susceptible to NK cell recognition from early 
stages of dysregulation. NK cells preferentially target tumor cells with low 
HLA class I expression. Although there is the potential for early NK cell 
recognition of transformed melanocytes, some studies have indicated that 
NK cells are poorly represented among tumor-infiltrating lymphocytes 
during melanoma progression, whereas others have demonstrated NK cells 
in all biopsies evaluated. Understanding how NK cells migrate into the 
tumor microenvironment is important to redirect NK cells to the tumor in 
the therapeutic setting. To appreciate the role of immunosurveillance 
during melanoma, the factors that influence NK cell recognition of nascent 
dysregulated melanocytes need to be identified. In turn, how these factors 
change at different stages of disease, both in primary lesions and 
metastases, must be deciphered. 
This involves characterizing the spatio-temporal expression of ligands 
during melanomagenesis, which hitherto has been poorly described, and 
the consequences of this on NK cell function (Burke et al., 2010). 
Surgery is still the elective treatment for most solid cancers. Radiotherapy, 
chemotherapy and biological agents (cytokines, vaccines, adjuvants and 
immune cells) are generally used as palliative therapy and most cellular 
immunotherapies remain experimental. A limitation of cellular 
immunotherapy is the disease stage that can be approached with biological 
therapy, and usually only after all other options have failed. This clinical 
constraint limits the efficiency of immunotherapy because it gives an 
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advantage to the tumor cell clones that have escaped the immune system. 
NK cells are crucial cytotoxic effectors that complement the action of 
CLTs. In particular, NK cells can influence other immune cells by 
producing cytokines that promote dendritic cell (DC) differentiation, 
antigen presentation and CTL activity, and can eliminate immature DCs, 
thus further improving the presentation of tumor antigens to T cells (Burke 
et al., 2010). One limitation to the use of NK cells in immunotherapy is the 
number of cells required. However large-scale production is now possible 
for human NK cells (Spanholtz et al., 2010). 
Recently, growing body of evidence indicates that a fine manipulation of 
the isoprenoid metabolism may constitute an important adaptive host 
response to stress, triggering immune response against tumor cells or 
infectious agents (Nassbaumer et al., 2011). Human peripheral blood 
Vγ9Vδ2 T cell subsets are the principal actors in monitoring the 
accumulation of phosphorylated isoprenoid metabolites (such as 
isopentenyl pyrophosphate, IPP). The reduced activity of the IPP-
consuming enzymes, farnesyl diphosphate synthase (FDPS) seems to be 
the key mechanism in stimulation of this cytotoxic T cell subset by tumor 
cells (Li et al., 2009). In light of this, several groups have shown that the 
specific FDPS inhibitor zoledronic acid, the most potent 
aminobisphoshonate (NBPs) currently available for clinical use, can be 
exploited to intentionally activate Vγ9Vδ2 T cell by inducing IPP 
accumulation in tumor cells or antigen professional cells (APC) (Dieli et 
al., 2007). 
Interestingly enough, NK cells can also be activated by the manipulation of 
the mevalonate pathway either by using zoledronate or statins 
(Nassbaumer et al., 2011; Gruenbacher et al., 2010) that are specific 
inhibitors of the hydroxymethylglutaryl coenzyme A (HMG-CoA) 
reductase, the first committed step of the mevalonate pathway acting 
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upstream to FDPS (Gazzerro et al., 2012). However, it has been reported 
that NK cells are not directly activated by isoprenoid products, like γδ T 
cells, but only indirectly through the action of a population of DC-like cells 
(Nassbaumer et al., 2011; Gruenbacher et al., 2010). This might be 
responsible of a delay in the first fast line of defense usually provided by 
NK cells. However this event seems not occur after treatment with 
mevalonate pathway inhibitors, leading to think that the accumulation of 
other isoprenoid end products might directly and immediately affect NK 
cell functions. 
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2. AIMS OF THE STUDY 
 
This study arises from some reflections on iPA, an endogenous end-
product derived from the mevalonate pathway, that has been already 
reported to exert a suppressor effect against various tumors in vitro and in 
vivo, even if its precise mechanism of action is until unknow. It is possible 
carrying out an efficacious anticancer strategy through different ways: 
using cancer cytotoxic drugs, anti-angiogenic agents or immune response 
activators able to attack specifically neoplastic cells. An important goal 
could be the identification of a drug with all these pleiotropic anticancer 
effects. 
In the light of these observations, the main aims of this work were: 
- to evaluate the ability of iPA to inhibit tumor progression through 
the interference with the angiogenic process, since angiogenesis is a 
key step to nourish the neoplastic mass, using human umbilical 
vein endothelial cells (HUVECs) as a suitable in vitro model of 
angiogenesis; 
- to study the antitumor activity of iPA against a model of cancer 
characterized by a highly angiogenic phenotype as melanoma, 
employing human melanoma cell line, A375 cells; 
- to verify the ability of iPA, due to its isoprenoid moiety and in 
analogy with IPP, to expande and activate selectively natural killer 
(NK) cells, the cytotoxic subset of innate immunity, using NK cells 
purified from healthy donors peripheral blood; 
- to provide key informations on the mechanism through which iPA 
exerts its biological effects in all the models studied. 
As additional deliverables it was possible to obtain basic informations 
about structure-activity relationship of iPA testing also its congeners, both 
isoprenoid, purine and structural analogues. 
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Moreover, it was clarified the non-involvement of the classical adenosine 
pathway in the biological effects exerted by iPA that are indeed mediated 
by intracellular targets. 
Data obtained in this work will allow to give novel insights into the 
biological activity of this promising endogenous isoprenoid showing 
pleiotropic effects as anticancer drug. 
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3. MATERIALS AND METHODS 
 
Materials 
iPA, IPP triammonium salt solution, adenine, isopentenyladenine, 
dipyridamole and erythro-9 (2-hydroxy-3-nonyl)-adenine (EHNA) 
powders as well as acridin orange powder were purchased from Sigma-
Aldrich (St. Louis, MO, USA); 5-iodotubercidin (5-Itu), PSB 1115 and ZM 
241385 from Tocris Bioscience (Bristol, UK); iPA analogues CM 223, CM 
224, CM 226 and CM 226 were provided by Prof. Ciuffedra (University of 
Milan); whilst carboxyfluorescein diacetate succinimidyl ester (CFSE) and 
LysoTracker- Red (DND-99) from Molecular Probes-Invitrogen (Paisley, 
UK). Anti-caspase-3 and -9, anti-PARP [poly (ADP-ribose) polymerase], 
anti-pChk1 (Ser296), anti-pATR (Ser428), anti-phospho p53 (Ser15), anti-
pHistone H2AX (Ser139), anti LC3-B, anti-pSTAT5 (Tyr 694) and anti-
STAT5, anti-phospho p44/42 MAPK (Thr202/Tyr 204), anti-p44/42 
MAPK, anti-phospho p38 MAPK (Thr180/Tyr182) and anti-p38 MAPK 
antibodies were all from Cell Signaling Technology (Danvers, MA, USA); 
anti p-AMPK and AMPK, anti-β-actin and anti-FDPS were from Abcam 
(Cambridge, UK). Anti-pan Ras and anti-tubulin were from Sigma-Aldrich 
(Dorset, UK). The MEK1/2-specific kinase inhibitor UO-126 was 
purchased from Cell Signaling technology (Beverly, MA). 
Cell cultures 
Human umbilical vein endothelial cells (HUVECs) were cultured on 1% 
gelatin-coated culture flasks with vent caps in M199 with heparin, 10% 
heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine and 
complete angiogenic factors (aFGF, bFGF, EGF, hydrocortisone and 
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heparin). The HUVECs were used at passages 2 to 6. Reagents were 
obtained from Sigma-Aldrich; aFGF, bFGF, and EGF were from Peprotech 
(London, UK). 
Human malignant melanoma cells (A375) were cultured in DMEM High 
Glucose (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 2 mM 
L-glutamine, 50 ng/ml streptomycin, 50 units/ml penicillin and 10% heat-
inactivated FBS (Hyclone Laboratories, Logan, UT, USA). 
All donors gave written informed consent in accordance with the 
Declaration of Helsinki to the use of their residual buffy coats for research 
purposes, with approval from the University Hospital of Salerno Review 
Board. Peripheral blood mononuclear cells (PBMC) from healthy donors 
were isolated over Ficoll-Hypaque gradients (lymphocyte separation 
medium; MP Biomedicals, Aurora, OH, USA). Human NK cells were 
negatively selected from PBMC by immunomagnetic procedure (NK-cell 
isolation kit; Miltenyi Biotec, Calderara di Reno, Italy). They were 
cultured for different time intervals in RPMI 1640 in the presence of IL-2 
at 100 U/ml alone or in combination with different concentrations of iPA. 
Also the human chronic myelogenous leukemia cell line K562 (ATCC) 
was maintained in RPMI 1640 (Invitrogen, San Diego, CA, USA) 
supplemented with 2 mM L-glutamine, 50 ng/ml streptomycin, 50 units/ml 
penicillin and 10% heat-inactivated FBS. All cell cultures were mantained 
at 37°C in humidified 5 % CO2 atmosphere. 
Drug treatments 
iPA was dissolved in DMSO (20 mM) and used at indicated 
concentrations. For each experiment, fresh dilutions were made from the 
stock solution and added to cell cultures at the indicated concentrations in 
serum-containing medium. 5-Itu was used in pre-treatment at a final 
concentration of 30 nM for 30 min. iPA analogues, as well as IPP, adenine 
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and isopentenyladenine were dissolved in DMSO and used at indicated 
concentrations. Also inhibitors and antagonists used were dissolved in 
DMSO. Human NK cells were stimulated for different time intervals in 
RPMI 1640 in the presence of IL-2 at 100 U/ml alone or in combination 
with different concentrations of iPA. 
Viability assay 
To determine cells viability, we used the colorimetric MTT metabolic 
activity assay. Cells were cultured in a 96-well plate at 37°C, with or 
without growth factors, and exposed to various concentrations of iPA, IPP, 
adenine and isopentenyladenine, as well as iPA analogues for 24 h. To 
each well, 10 µl of MTT solution (5 mg/ml, in water) was added for 4 h. 
The resultant formazan crystals were dissolved in 100 µl of solubilization 
solution (10% Triton X-100 and 0.1 N HC1 in isopropanol), and the 
absorbance intensity was measured on a microplate reader 
(ThermoScientific, Basingstoke, UK) at 595 nm with a reference 
wavelength of 650 nm. All experiments were performed in triplicate, and 
the relative cell viability was expressed as a percentage comparison with 
the untreated control cells. 
Proliferation assay by BrdU incorporation 
Cell proliferation was evaluated by measuring BrdU incorporation into 
DNA (BrdU colorimetric assay kit; Roche Applied Science, South San 
Francisco, CA, USA). Endothelial or melanoma cells, pretreated or not 
with 5-Itu (30 nM, 30 min) or with adenosine receptors antagonists, were 
treated with increasing concentrations of iPA. Cells were seeded into 96-
well plates for the indicated time at 37°C. Newly synthesized BrdU-DNA 
was determined on an ELISA plate reader (ThermoScientific) at 450 nm. 
Chapter 3                                                        MATERIALS AND METHODS 
34 
Liquid chromatography–coupled tandem mass spectrometry (LC-
MS/MS) and sample preparation 
iPA and iPAMP extraction was performed with ice-cold acetone. Briefly, 4 
volumes of ice-cold (-20°C) acetone were added to 100 µl of cell lysate 
and incubated for 3 h at -20°C, to allow protein precipitation. Then, 
insoluble proteins were precipitated by centrifugation (10,000 g, 10 min, 
4°C), and the supernatant was collected, dried in vacuo, and resuspended in 
500 µl of H2O:acetonitrile (1:1) for mass spectrometric analysis. LC-
MS/MS analysis was performed with the Accela 600 pump and Accela 
AutoSampler system equipped with an LTQ-Orbitrap XL mass 
spectrometer (ThermoScientific). The mixture separation was performed 
with a Jupiter C4 column (50×2.00 mm; Phenomenex, Torrance, CA, 
USA) with a linear gradient from 2% of solution A (H2O and 0.05% acetic 
acid) to 50% of solution B (acetonitrile and 0.05% acetic acid) for 25 min 
at a flow rate of 100 µl/min. The electrospray ionization (ESI) ion source 
was set in positive ion mode, and the capillary temperature was kept at 
240°C, with the sheath and the auxiliary gas flow rates set at 8 and 2, 
respectively. The mass spectrometer was set to operate in selected-reaction 
monitoring (SRM) mode. The transitions of the protonated iPA and 
iPAMP to their product ions were recorded at m/z 336.1578→204.0476 
and at m/z 416.1346→204.0675, respectively. The collision energy was set 
at 30. All experiments were performed in triplicate. 
Cell cycle analysis 
Endothelial or melanoma cells were plated in 100-mm dishes. To 
synchronize endothelial cells at the G1/S interface, they were serum starved 
in medium with 0.5% serum for 18 h. Cells pretreated or not with 5-Itu (30 
nM, 30 min) were treated with iPA. After 24 h, the cells were collected, 
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fixed in 70% ethanol, and kept at -20°C overnight. Propidium iodide (PI; 
50 µg/ml) in PBS containing 100 U/ml DNase-free RNase was added to 
the cells for 15 min at room temperature. The cells were acquired by a 
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). The 
analysis was performed with ModFit LT v3.2 (Verity Software House, 
Inc., Topsham, ME, USA); 10,000 events, corrected for debris and 
aggregate populations, were collected. 
Apoptosis analysis 
Quantitative assessment of apoptosis was analyzed by anti-human annexin 
V (BMS147FI; eBioscience, San Diego, CA, USA) and PI staining. 
Briefly, cells grown in 100-mm dishes were harvested with trypsin and 
washed in PBS. The cells were resuspended in annexin V binding buffer 
(10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) and 
stained with annexin V-FITC and then with PI at room temperature for 15 
min in the dark. The cells were acquired by flow cytometer within 1 h after 
staining. At least 10,000 events were collected, and the data were analyzed 
by CellQuest Pro software (BD Biosciences). 
Western blot analysis 
Cells treated as described were washed with ice-cold phosphate-buffered 
saline and scraped into lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% 
Triton X-100, 0.5% deoxycholic acid, 10 mg/ml leupeptin, 2 mM 
phenylmethylsulfonyl fluoride and 10 mg/ml aprotinin). After removal of 
cell debris by centrifugation (14,500 g for 20 min at 4°C), the proteins 
were estimated. From 10 to 30 µg of proteins were loaded on 6- 15% SDS–
polyacrylamide gels under reducing conditions and then transferred to 
nitrocellulose membranes. The membranes were blocked with 5% nonfat 
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dry milk (Bio-Rad, Richmond, CA, USA) and incubated with the specific 
antibody. After washes, the filters were incubated for 1 h at room 
temperature with horseradish peroxidase–conjugated secondary antibody. 
The membranes were stained by using a chemiluminescence system (ECL; 
Amersham Biosciences, Amersham, UK) and then exposed to X-ray film 
(Amersham Biosciences). Immunoreactive bands were quantified with 
Quantity One 1-D analysis software (Bio-Rad). If necessary, the 
membranes were stripped and reprobed with another antibody. 
Wound-healing assay 
Confluent HUVEC monolayers were grown on 1% gelatin coated 24-well 
plates. Endothelial cells, pretreated or not with 5-Itu (30 nM, 30 min), were 
treated with increasing concentrations of iPA and wounded with a 200-µl 
tip. Images of wound closure were captured with a phase-contrast 
microscope (AF6000 LX; Leica Microsystems GmbH, Wetzlar, Germany) 
in time-lapse video microscopy every 10 min with the Leica LAS AF 
software (×10). The width of the wound from each image was measured at 
selected time points (0, 6, 12, and 24 h) with ImageJ 1.45 software (U.S. 
National Institutes of Health, Bethesda, MD, USA). The degree of wound 
regeneration was calculated as the percentage of the remaining cell-free 
area compared with the vehicle control. 
Endothelial cell gel invasion assay 
A Matrigel (BD Biosciences, San Jose, CA, USA) invasion assay was 
performed using cell culture inserts (3.0 µm) for 24-well plates (BD 
Falcon; BD Biosciences) coated with Matrigel (300 µg/ml) diluted in a 
coating buffer (0.01 M Tris and 0.7% NaCl, pH 8) for 2 h at 37°C. 
Endothelial cells were stained with the fluorescent probe CFSE (3µM) and 




 cells/well) on cell culture inserts in 250 µl of serum-free 
medium. The lower compartments were filled with M199 medium (10% 
FBS) containing complete angiogenic factors as a chemotactic stimulus. 
The cells were treated with increasing concentrations of iPA, with or 
without 5-Itu pretreatment (30 nM, 30 min). After incubation of the cells 
for 18 h at 37°C, serial micrographs (9 microscopic fields/well) of invading 
cells were obtained with an inverted fluorescence microscope (AF6000 
LX; Leica) at ×10. The cells were quantified by ImageJ 1.45 software. 
Background levels of invading cells in the absence of chemotactic factors 
(chemokinesis) were subtracted from all the experimental points. 
Capillary-like tube formation on gel 
Prechilled 48-well plates were coated with Matrigel, which was allowed to 
polymerize for 30 min at 37°C. Endothelial cells, pretreated or not with 5-
Itu (30 nM, 30 min), were seeded (1×10
4
 cells/well) in 250 µl of complete 
medium. iPA at the indicated concentrations was added. After 6 h, 
capillary-like tube formation was examined under an inverted phase 
microscope (×4) and photographed. The number of network intersections 
was quantified by ImageJ 1.45 software. 
Gel plug angiogenesis assay 
Liquid gel (Cultrex BME Growth Factor Reduced; Trevigen, Gaithersburg, 
MD, USA) was prepared at 4°C and combined with iPA (5 µM), IPP (5 
µM), or 5-Itu (30 nM) in the presence or absence of FGF2 (27 nM) and 
injected subcutaneously (0.5 ml/mouse) into the flank of 6–8-wk-old 
C57BL/6 mice (Charles River, Calco, Italy). Cultrex with PBS alone was 
used as a negative control. At 1 wk after injection, the mice were 
euthanized, and the plugs were harvested, weighed, and processed for RT-
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qPCR analysis. When specified, the harvested plugs were divided into 
halves: one half underwent RT-qPCR analysis, and the other half was 
embedded in Tissue Tec optimal cutting temperature (OCT) compound 
(Sigma-Aldrich), snap-frozen by immersion in liquid nitrogen-cooled 
isopentane, and analyzed by immunofluorescence microscopy. 
Immunofluorescence was performed on 5-µm frozen sections by staining 
with anti-CD31 antibody (red) and DAPI (blue). The sections were 
examined under an Axioplan 2 epifluorescence microscope (Carl Zeiss 
Microscopy, Thornwood, NY, USA) at ×200. 
Endothelial-melanoma cells co-culture 
A co-culture was performed using cell culture inserts (0.9 µm) for 12-well 










seeded on cell culture inserts and treated with increasing concentrations of 
iPA (1-10 μM). After incubation of the cells for 24 h at 37°C, inserts were 
placed in 12-well plates containing the endothelial cells for 24 h of co-
culture. Endothelial cells were then fixed and stained with crystal violet 
(0.5% w/v in methanol 20%) and solubilized with a solution of acetic acid 
(33% in water). The absorbance intensity was measured on a microplate 
reader (ThermoScientific, Basingstoke, UK) at 570 nm. 
Tumor clonogenic assay 
Melanoma cells were seeded in 6-well plate (200 cells/well) and treated at 
time 0 h with increasing concentrations of iPA alone (1-10 μM) with or 
without the pre-treatement with 5-Itu (30 nM, 30 min) and monitored for 
ten days. Colonies are fixed and stained with crystal violet (0.5% w/v in 
methanol 20%) and photographed. 
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Flow cytometric analysis of autophagy 
Briefly, melanoma cells grown in 100-mm dishes were harvested with 
trypsin and washed in PBS. The quantification of acidic vesicular 
organelles (AVO), as a marker of autophagy, was detected by staining 
melanoma cells (1×10
4
) with lysosomotropic agent acridine orange (2 
µg/ml) for 15 min at 37°C. LysoTracker-Red DND-99 
(excitation/emission, 577/590 nm), a red-fluorescent dye for labeling and 
tracking acidic organelles in live cells, was added to melanoma cells at a 
final concentration of 50 nM for 30 min at 37°C. The cells stained were 
measured by flow cytometry (Flow Cytometer, BD Biosciences, San Jose, 
CA, USA). For autofluorescence, cells were analyzed without any staining. 
The data were analyzed by FlowJo software (TREE STAR, Inc., San 
Carlos, CA). 
Proliferation assay by CFSE incorporation 
Proliferation was assessed by flow-cytometric analysis of CFSE 
(Molecular Probes, Eugene, Oregon) dilution as described. To this end 
freshly isolated human NK cells were labeled by incubation at 5×10
6
/ml in 
PBS with 3μM CFSE at 37° for 10 min under gentle agitation, washed and 
resuspended in RPMI 1640 complete culture medium and cultured at the 
concentration of 4×10
5
 cells/well in a round bottom, 96-well plate. 
Stimulation was effected by addition of IL-2 at 100 U/ml alone or in 
combination with different concentrations of iPA for different time 
intervals (3-8-10 days). A portion of the population was arrested at the 
parent generation using mitomycin C (Sigma-Aldrich). All data were 
acquired by CellQuest Pro software while the percentage of total 
proliferated NK cells, the maximum number of cells division, and the 
numerical values for proportions of proliferated cells at each cell division 
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were obtained by using ModFit LT software (Verity Software House, 
USA). 
mAbs and cytofluorimetric analysis 
NK phenotype was assessed by flow cytometry. Fluorochrome-conjugated 
monoclonal antibodies (mAbs) against CD56, CD3, CD69, CD107a, 
NKp30, NKp44, NKp46, NKG2D, as well as the corresponding isotype 
immunoglobulin of control were purchased from BD Biosciences (San 
Diego, CA, USA). Data were collected using a FACSCalibur flow 
cytometer (Becton Dickinson, USA) and analyzed by CellQuest Pro 
program (Becton Dickinson, San Jose, CA). Data are expressed as 
logarithmic values of fluorescence intensity. 
Flow cytometric assay of NK-cell cytotoxicity 
Purified NK cells of healthy donors were stimulated with IL-2 in the 
presence or absence of iPA and then used as effectors against K562 human 
cell line using CFSE NK cytotoxicity assay. Briefly, the K562 target cells 
were labeled with CFSE. Target cells were mixed with effector cells at 
different E:T ratios and incubated at 37° C for 4 hours in 96-well round-
bottom plates in a final volume of 200 μl of RPMI 1640 complete medium 
per well. In parallel, target cells were incubated alone to measure 
spontaneous cell death. At the end of the incubation time, the total contents 
of the U bottom plate were transferred to Falcon tubes, put in ice and 
incubated with PI 30 μg/ml for 5 min, followed by flow cytometric 
analysis within 1 h. During data acquisition, “a live gate” was set on 
CFSE-stained target cells population using an FL1-histogram, and 5000 
target events were collected. For data analysis, target cells (R1) were 
further analyzed in a F1/F3 dot plot where dead target cells (CFSE+PI+) 
were visualized on upper right quadrant. The percentage of target cell 
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death (cytotoxicity) was calculated as follows: 
Cytotoxicity(%) = Dead target cells in the sample(%)-Spontaneously dead target cells(%) 100 
                                                              100- Spontaneously dead target cells (%)                
 
CD107a mobilization assay 
Activated NK cells were cultured in complete medium with or without 
K562 cells at 1:1 E:T ratio in the presence of PE-conjugated CD107a/IgG1 
antibody (BD Pharmingen) in U bottom 96 well plates. After 1 h, Brefeldin 
A (5µg/ml, Sigma-Aldrich St. Louis, MO, USA) was added to cultures for 
an additional 3 h of incubation. At this time cells were collected, washed 
with PBS with 2% FBS, stained with anti-CD56 PE-Cy5 (BD 
Biosciences), anti-CD3 FITC (BD Biosciences) and analyzed by flow 
cytometry. 
Cytokines secretion measurements 
Purified NK cells were stimulated with IL-2 in the presence or absence of 
iPA. After 18h activated NK cells (2x10
5
) were washed twice and mixed 
with 4×10
5 
K562 cells in 200μl of complete medium. Cells were incubated 
for the indicated time. Thereafter, supernatants were collected and stored at 
-20°C pending measurement while cell pellets were analyzed for the 
surface expression of CD69 NK activating marker. The concentration of 
IFN-γ was measured by ELISA assay according to manufacturer’s 
specification (R&D Systems and Biosource International) while the 
concentrations of TNF-α, RANTES, MIP-1α were quantified by a 
multiplex immunoassay (Fluorokine MAP cytokine multiplex kits, R&D 
Systems and Biosource International) according to manufacturer’s 
instructions. 
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Farnesyl diphosphate synthase assay 
Cells were washed twice with 1 ml ice-cold PBS and scraped in 0.2 ml ice-
cold lysis buffer (Imidazol 40 mM and DTT 50 mM). The cell lysate was 
centrifuged at 10000 rpm for 5 min and the supernatant was used for FDPS 
assay. FDPS was assayed in 150 µl containing 25 mM HEPES, pH=7.4, 2 
mM MgCl2, 1 mM dithiothreitol, 5 mM KF, 1% n-octyl-β-
glycopyranoside, 3.3 µM [4-14C] IPP (18 Ci/mmol), 3 µM unlabeled IPP 
and 20 µM geranyl diphosphate. Reactions were started adding 40 µl of 
lysate containing 100 µg of total protein and incubated for 45 min at 37°C. 
Reactions were stopped by the addition of 150 µl 2.5 N HCl in 80% 
ethanol containing 100 µg/ml farnesol as a carrier. The samples were 
hydrolyzed for 30 min at 37°C to convert the FDP to farnesol and 
neutralized by the addition of 150 µl of 10% NaOH. The reaction product 
(farnesol) was extracted into 1 ml of n-hexane and an aliquot (200 µl) of 
the organic phase was used for radioactivity counting. One unit of enzyme 
activity is defined as the amount of enzyme required to synthesize 1 pmol 
of FDP/min. Parallel samples were assayed to evaluate the total and the 
non-specific radioactivity. In all experiments, enzyme assays were carried 
out in duplicate. The coefficient percentages (CV%) of intra- and inter-
assay variation were 3% and 4%, respectively. 
RAS-GTP selective precipitation 
Ras-GTP was identified by precipitation with Gst-tagged Raf1-RBD (Ras 
Activation Assay Kit; Cytoskeleton Inc., Denver, CO, USA) followed by 
immunoblotting. Cellular lysates were prepared according to the 
manufacturer's instructions. The following antibodies were used: mouse 
monoclonal anti-human pan-Ras (Sigma-Aldrich Inc St Luis, MO, USA or 
Cytoskeleton Inc.), rabbit monoclonal anti-human phospho-STAT5 (p-
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STAT5; Tyr 694), rabbit polyclonal anti-human STAT5, rabbit monoclonal 
anti-human phospho-p44/42 MAPK (p-ERK, Thr202/Tyr 204), rabbit 
monoclonal anti-human p44/42 MAPK, mouse monoclonal anti-human 
phospho-p38 MAPK (Thr180/Tyr182) and rabbit monoclonal anti-human 
p38 MAPK (Cell Signaling Technology, Danvers, MA), rabbit polyclonal 
anti-human β-actin and rabbit polyoclonal anti-human FDPS (Abcam, 
Cambridge, UK). 
Statistical analysis 
Statistical computations were performed with Prism 6.0 software 
(GraphPad, San Diego, CA, USA). Data obtained from multiple 
experiments were calculated as means ± SD and analyzed for statistical 
significance by using the 2-tailed Student t-test, 1- or 2-way ANOVA for 
independent groups, with the Tukey or Bonferroni correction for multiple 


















4.1 iPA inhibits endothelial cell proliferation 
To investigate the effects of iPA (Fig. 7A) on the angiogenesis process, we 
used, as a common model of angiogenesis in vitro, HUVEC cells 
stimulated with proangiogenic growth factors or in a quiescent state, for 
comparison. First, we evaluated cell viability by the MTT assay. The 
treatment of endothelial cells for 24 h with increasing concentrations of 
iPA (0.3–20 µM) inhibited viability in a dose-dependent manner (IC50 
0.98 µM; Fig. 7B). Up to 5 µM, iPA showed an inhibitory effect on the 
viability of endothelial cells that was specific for cells stimulated by pro-
angiogenic factors vs quiescent cells. Only the highest concentrations of 
iPA tested (>10 µM) exerted a slight cytotoxic effect inhibiting also the 
viability of quiescent endothelial cells. Then, to evaluate whether iPA 
inhibits the proliferation rate of endothelial cells, we performed a more 
sensitive BrdU proliferation assay in a kinetic analysis at 24 and 48 h. iPA 
induced a concentration-and time-dependent block of proliferation (IC50 
0.67 µM; Fig. 7C); after a treatment of 48 h, a near-total ablation of 
proliferation was clear at concentrations as low as 1.25 µM (Fig. 7D). 
From these data, we selected the 1- to 10-µM range and the 24-h maximum 
time point of iPA treatment for all further experiments. 




Figure 7. iPA inhibited endothelial cell proliferation. A) Structure of iPA. B) 
Histogram shows the inhibition of the viability of endothelial cells treated with increasing 
concentrations of iPA (0.3–20 µM) and stimulated (solid bars) or unstimulated (shaded 
bars) with proangiogenic growth factors for 24 h, evaluated by MTT assay. C, D) 
Inhibition of proliferation of endothelial cells, pretreated or not with the ADK inhibitor 5-
Itu (30 nM, 30 min), was confirmed by a BrdU proliferation assay for 24 h (C) and 48 h 
(D). Results are expressed as means ± SD of 3 independent experiments performed in 
triplicate. *P < 0.05, **P < 0.01, ***P < 0.001 vs control (cells untreated or treated 
without 5-Itu: ANOVA). 
 
4.2 The peculiar structure of iPA is responsible for the 
antiproliferative effects on endothelial cells 
Since iPA is a modified adenosine characterized by an isopentenyl chain 
linked to the nitrogen at position 6 of the purine base, we evaluated, by 
comparison, the effects of structural analogues of iPA to understand 
whether the observed effects of iPA were ascribable to the purine base or 
to the isopentenyl chain, in order to identify the portion of the molecule 
responsible for the anti-proliferative effect observed in endothelial cells. 
We therefore evaluated, by MTT viability assay, the effects of 
isopentenylpyrophosphate (IPP), adenine and N6-isopentenyladenine (Fig. 
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8 A-C). Whereas adenosine is already known to stimulate angiogenesis 
(Auchampach, 2007), neither IPP, adenine nor isopentenyladenine affected 
endothelial cell viability (Fig. 8). These data suggest that the 
antiproliferative effects of iPA cannot be ascribed to the isoprenoid chain 
alone or to the purine group, but are due to the peculiar structure of iPA 
composed of the specific combination of the adenosine moiety and the 
isopentenyl chain. Thus, depriving the overall structure of iPA of its 
individual components, namely ribose, adenine and isopentenyl chain, the 
molecule loses its activity. 
As described above, iPA has no activity in vivo when administered 
intraperitoneally because of pharmacokinetic instability (Colombo et al., 
2009). In order to find iPA analogues with a major stability in vivo, a series 
of iPA analogues differently substituited in N6 position were synthesized 
by the group of Prof. Ciuffedra (Ottria et al., 2010). Among these, we 
tested adenosine analogues characterized by a phenyl ring in N6 position 
(CM 223), or isopentyl (CM 224), or allylic (CM 226) or butyl (CM 227) 
chain. The Figure 9 shows the effects of these structural synthetic 
analogues on the viability of the endothelial cells. Whereas CM 224 did 
not exerted any effect on endothelial cell viability (Fig. 9B), CM 223 
resulted to be cytotoxic on proliferating and quiescent endothelial cells 
(Fig. 9A). The compounds CM 226 and 227, harbouring respectively 
allylic and butyl chain, were less potent compared to iPA, inhibiting 
endothelial cells viability in a reduced range of the concentrations (Fig. 
9C-D). 
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Figure 8. Peculiar structure of iPA was responsible for the antiproliferative effects 
on endothelial cells. Histograms show the effects on the viability of endothelial cells 
treated with increasing concentrations of the (A) IPP (7.5–30 µM), (B) nitrogenous base 
adenine (0.6–10 µM) and (C) N6-isopenteyladenine stimulated (solid bars) or 
unstimulated (shaded bars) with proangiogenic growth factors for 24 h, evaluated by MTT 




Figure 9. N6-substituted iPA derivatives were less active compared to iPA. 
Histograms show the effects of adenosine analogues characterized by a phenyl ring in N6 
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position (CM 223, A), or isopentyl (CM 224, B), allylic (CM 226, C) or butyl (CM 227, 
D) chain on the viability of the endothelial cells stimulated (solid bars) or unstimulated 
(shaded bars) with proangiogenic growth factors for 24 h, evaluated by MTT assay. 
Results are expressed as means±SD of 2 independent experiments performed in triplicate. 
**P < 0.01, ***P < 0.001 vs. control (cells untreated), ANOVA. 
 
In the light of the results obtained by our research group and by others 
(Ottria et al., 2010), we are able to have a basic possible structure-activity 
relationship of iPA (Fig. 11), indispensable to better understand which 
portion of the structure has to be preserved in order to synthesize new and 
more potent analogues of iPA able to have a long plasma half-life, useful 
to the in vivo administration. 
 
Figure 10. Possibile structure-activity relationship of iPA 
 
4.3 The classical adenosine pathways are not involved in biological 
effects exerted by iPA 
 
Since iPA is a derivative of adenosine and so it could potentially bind to 
adenosine receptors to exert its biological effects on endothelial cells, we 
Chapter4                                                                                          RESULTS 
50 
treated cells with different antagonists of adenosine receptors and 
inhibitors of adenosine uptake. 
Based on mRNA levels and stimulation of adenylate cyclase, HUVEC 
cells have been reported to preferentially express A2A adenosine receptors, 
while microvascular cells express A2B. Neither cells expressed A1 or A3 
receptors (Feoktistov et al., 2002). Both the A2A and A2B receptors are 
however thigtly implicated with angiogenesis (Auchampach, 2007). To 
verify whether iPA could be recognized as adenosine by cells interacting 
thus with adenosine receptors, that are G-protein coupled receptors, in the 
extracellular environment, we pre-treated endothelial cells with specific 
and selective A2A and A2B antagonists, respectively ZM241385 (1 µM, 
30 min) (Fig. 11A) and PSB1115 (1 µM, 30 min) (Fig. 11B). The pre-
treatment with these antagonists did not affect in any way the inhibitory 
effects of iPA on endothelial cells proliferation, therefore excluding their 
involvement in the action of iPA at least in this model. 
To evaluate if iPA could be substrate of the adenosine deaminase, an 
enzyme involved in purine metabolism, we also pre-treated endothelial 
cells with erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA, 10 µM, 30 
min), an inhibitor of this enzyme, and then we added iPA at increasing 
concentrations (Fig. 11C). Moreover, since the passage of nucleosides 
across plasma membranes or between intracellular compartments occurs 
primarily via specialized nucleoside transporter proteins (King et al., 
2006), to assess whether iPA needs to be transported into the cell via these 
transporters, in particular those sensitive to dipyridamole, we used in pre-
treatment dipyridamole (10 µM, 30 min), a pharmacological inhibitor of 
nucleoside transporters (Fig. 11C). The graph clearly shows that iPA is not 
a substrate of adenosine deaminase since the antiproliferative action of iPA 
did not decrease following the inhibition of this enzyme. Moreover, not 
even the inhibition of nucleoside transporters was able to revert inhibitory 
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effects of iPA, suggesting that iPA is not recognized as nucleoside and is 
not transported into the cell through dipyridamole-sensitive adenosine 
carriers (Fig. 11C).  
 
 
Figure 11. iPA did not act as an adenosine mimetic. iPA is not recognised as adenosine 
mimetic, since neither the A2A receptor (ZM 241385, 1 µM, 30 min A) nor the A2B 
receptor (PSB 1115, 1 µM, 30 min B) antagonists were able to revert the antiproliferative 
effect of iPA in endothelial cells, as showed by BrdU proliferation assay. iPA is not 
catabolised by adenosine deaminase and does not entry into the cells by dipyridamole-
sensitive nucleoside transporters, since EHNA (inhibitor of adenosine deminase, 10 µM, 
30 min) and dipyridamole (inhibitor of nucleoside transporters, 10 µM, 30 min) did not 
affect the effect of iPA on the endothelial cells viability (C). Results are expressed as 
means±SD of 2 independent experiments performed in triplicate. ***P < 0.001 vs. control 
(cells untreated or treated with iPA), ANOVA. 
 
 
4.4 iPA must be phosphorylated into iPAMP to exert its biological 
effects through AMPK activation 
To understand the molecular mechanism by which iPA exerts its 
antiproliferative effects, we pretreated endothelial cells with 5-Itu, an ADK 
inhibitor (ki=30 nM). We wanted also to evaluate whether iPA is a 
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substrate of this enzyme. 5-Itu-pretreated endothelial cells (30 nM, 30 min) 
were exposed to increasing concentrations of iPA for 24 and 48 h (Fig. 7C, 
D). Of note, we found that 5-Itu pretreatment completely reversed the 
inhibitory effect of iPA on endothelial cells proliferation at each 
concentration tested, suggesting that iPA must be phosphorylated into 
iPAMP by ADK inside the cell to exert its inhibitory effects on endothelial 
cells. To demonstrate the effective formation of iPAMP, we analyzed the 
intracellular levels of iPA and iPAMP by LC-MS/MS. Cells were treated 
with iPA at different time points (0, 1, and 3 h), as reported above. Treated 
and untreated samples were lysed and subjected to a protein precipitation 
procedure, to isolate cell metabolites before LC-MS/MS analysis, 
performed in SRM mode. Two chromatographic peaks were obtained for 
iPA and iPAMP at 15.2 and 0.9 min retention time, respectively, and then 
integrated to give the areas reported in Fig. 12. iPA was efficiently 
internalized (Fig. 12A) and converted into iPAMP (Fig. 12B) in a time-
dependent manner. Moreover, to demonstrate that iPA is converted within 
the cells into iPAMP by ADK, we treated the cells with 5-Itu before iPA 
administration and then performed an MS analysis, as previously shown.  
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Figure 12. iPA was effectively converted in its monophosphorylated form, iPAMP, 
inside the cells. A, B) Overlapping chromatographic peaks (left panel) and the 
corresponding peak areas (right panel) of iPA (A) and iPAMP (B), obtained after different 
incubation times by LC-MS/MS in SRM mode. C) iPA/ iPAMP species ratio in cells 
treated with iPA alone and subjected to 5-Itu pretreatment. Results are expressed as means 




Our results clearly showed a strong incremental change in iPA/iPAMP 
ratio as a consequence of ADK inhibition. Indeed, as reported in Fig. 12C, 
the iPA/iPAMP ratio moved from 5:1 to 30:1 when the cells were 
pretreated with 5-Itu to inhibit ADK activity. We also observed that iPA 
internalization was slightly decreased by 5-Itu pretreatment (data not 
shown). These data, taken together, demonstrate that 5-
monophosphorylation of iPA to form iPAMP, catalyzed by ADK, is 
indispensable for the activity of iPA and that iPAMP is therefore 
responsible for all the biological effects observed.  
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As proof of the correlation between iPAMP and AMP the treatment of 
endothelial cells with increasing concentrations of iPA (1–10 µM) resulted 
in persistent, dose- and time-dependent increases in AMPK activity, as 
reflected by the phosphorylation induction of AMPK-α catalytic subunit 
(Fig. 13). Induction of AMPK activity was detected as early as 6 h after 
iPA administration and remained elevated during 24 h of iPA exposure. 
Furthermore, the increase in AMPK activity was completely reversed by 5-





Figure 13. iPA activated AMPK, inducing its phosphorylation. Dose- and time-
dependent increase in AMPK activity was analyzed by Western blot. Endothelial cells, 
grown in serum containing medium, were treated with iPA at the indicated concentrations, 
with or without 5-Itu pretreatment (30 nM, 30 min) for 6, 18, and 24 h. Tubulin served as 
the loading control. Blots were stripped and reprobed with the different antibodies. Data 
are representative of 3 different experiments with similar results. Histograms (right 
panels) report the results of the quantitative analysis (arbitrary units, pAMPK/ 
AMPK/tubulin) as means ± SD of 3 independent experiments. *P <0.05, **P < 0.01, 
***P < 0.001 vs. control or treatment without 5-Itu; ANOVA. 
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4.5 iPA induces S-phase stasis and apoptosis, activating the 
intrinsic caspase cascade and DNA damage machinery 
To investigate the nature of the antiproliferative action of iPA, we 
evaluated its effect on the progression of the endothelial cell cycle by flow 
cytometry, analyzing the distribution of cells in the different phases of cell 
cycle at increasing times in iPA-treated cells, pretreated or not with 5-Itu 
(30 nM, 30 min), in comparison with untreated cultures. Results in Fig. 
14A (bottom panels) showed that treatment of endothelial cells with 5 and 
10 µM of iPA for 24 h resulted in an increase in cells in the S phase, 
compared with that in the control-treated cells. The S-phase stasis induced 
by iPA was completely reversed by 5-Itu pretreatment, demonstrating also 
that the S-phase block was mediated by the iPAMP derivative. Beyond the 
S-phase stasis, we observed that the treatment of iPA at 5 and 10 µM was 
associated with the appearance of a cell population with a reduced DNA 
content (hypodiploid), usually referred to as sub-G0, characteristic of 
apoptosis. To confirm the induction of apoptosis, we performed an annexin 
V binding assay in endothelial cells treated with increasing concentrations 
of iPA, pretreated or not with 5-Itu (30 nM, 30 min). As shown in Fig. 
14B, both annexin V-positive (early apoptotic cells, bottom right quadrant) 
and annexin-PI double-positive cells (late apoptotic cells, top right 
quadrant) were significantly increased in cells treated with 5 and 10 µM 
iPA (5 µM, 20.2±5.1 and 11.3±2.5%; 10 µM, 23.5±11.4 and 25.8±9.7%, 
respectively), compared to untreated cells (3.8±0.8 and 4.6±1.1%, 
respectively) (Fig. 14B). The results confirmed apoptosis induction by iPA. 
Also in this case, phosphorylation into iPAMP was essential in the 
induction of apoptosis, since the pretreatment with 5-Itu restored the 
control conditions. To corroborate the proapoptotic effect of iPA, we 
examined the expression of caspases and key proteins that play essential 
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roles in apoptosis induction. Treatment with iPA strongly induced the 
expression of cleaved caspase-9 and -3, as well as cleaved PARP, in a 
time- and concentration-dependent manner (Fig. 14C). We therefore 
demonstrated that iPA activated the intrinsic caspase cascade, leading to 
caspase-9 cleavage followed by caspase-3 activation that resulted in 
PARP-1 cleavage and execution of the apoptotic cell program. To 
investigate whether iPA induces cell cycle arrest and apoptosis after the 
activation of typical DNA damage checkpoints, such as the ATR-Chk1 
pathway and p53, we analyzed the phosphorylation and hence activation of 
ATR at Ser428, Chk1 at Ser296, p53 at Ser15, and histone H2AX at 
Ser139. We found that iPA elicited the phosphorylation of all these 
proteins in a concentration-dependent manner, suggesting involvement of 
the DNA damage pathways in the proapoptotic effects elicited (Fig. 14D). 
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Figure 14. iPA induced S-phase stasis of endothelial cells and apoptosis via caspases 
and DNA damage. A) Distribution of endothelial cells in the different phases of the cell 
cycle in iPA-treated (1–10 µM) cells, pretreated or not with 5-Itu (30 nM, 30 min), and in 
parallel untreated cultures. Histograms show results of the quantitative analysis of cells in 
each phase of the cell cycle, expressed as a percentage. Results are representative of 3 
independent experiments performed in duplicate and are expressed as means ± SD. *P 
<0.05, ***P < 0.001 vs. control; ANOVA. B) Annexin V binding assay in endothelial 
cells treated with iPA (1–10 µM), pretreated or not with 5-Itu (30 nM, 30 min). Panels 
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show quantitative analysis of annexin V-positive cells (apoptotic cells, bottom right 
quadrant), PI-positive cells (necrotic cells, top left quadrant), and annexin-PI positive cells 
(late apoptotic cells, top right quadrant). Results are representative of 3 independent 
experiments performed in duplicate and are expressed as means ± SD. **P < 0.01, ***P < 
0.001 vs. control or treatment without 5-Itu; ANOVA. C) Concentration- and time-
dependent increase of the intrinsic apoptosis pathway by expression of cleaved caspase-3 
and -9, as well as of cleaved PARP, determined by Western blot analysis. Endothelial 
cells, grown in serum-containing medium, were treated with iPA (1–10 µM) for 6, 18, and 
24 h. Tubulin served as the loading control. Same tubulin is shown for filters that were 
stripped and reprobed with different antibodies. Data are representative of 3 independent 
experiments. Histograms (right panels) report the quantitative analysis (arbitrary units) 
expressed as means ±SD of 3 independent experiments with similar results. *P < 0.05, 
***P < 0.001 vs. control; ANOVA. D) Analysis of the DNA damage pathway. 
Endothelial cells, grown in serum-containing medium, were treated with iPA (1–10 µM) 
for 1 and 18 h. Phosphorylation of ATR at Ser428, Chk1 at Ser296, p53 at Ser15, and 
histone H2AX at Ser139 were determined by Western blot analysis at 1 h (p-ATR and p-
Chk1) and 18 h (p-p53 and p-HistoneH2AX). Tubulin served as the loading control. 
Histograms (right panels) report the quantitative analysis (arbitrary units) expressed as 




4.6 iPA inhibits endothelial cell migration, invasion, and capillary 
network formation 
Angiogenesis involves the formation of new microvessels, their growth 
and stabilization, and a series of phases besides proliferation that include 
migration of endothelial cells toward an angiogenic stimulus, invasion into 
the extracellular matrix, and proliferation and organization into 3-
dimensional tube-like structures. To assess whether iPA influences not 
only the proliferation but also the migratory and invasive properties of 
endothelial cells, we performed the wound-healing and Matrigel invasion 
assays, respectively. A monolayer of endothelial cells was scratched with a 
pipette tip, and the subsequent closure of the wounded area was monitored 
every 10 min by time-lapse video microscopy, to evaluate the capacity for 
cell migration. Control endothelial cells forming the boundaries of the 
wound migrated, filling the wound within 24 h. Treatment with iPA at all 
concentrations inhibited endothelial cell migration and therefore did not 
allow the healing of the wound at 24 h (Fig. 15A, B). The invasion of the 
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endothelial cells through the extracellular matrix was also inhibited by iPA 
in a concentration-dependent manner, as demonstrated by the count of 
CFSE-positive endothelial cells that invaded the Matrigel coating (Fig. 
15C). It was clear once again that these effects were attributable to iPAMP, 
because the pretreatment of endothelial cells with 5-Itu reversed almost 
completely the anti-migratory and anti-invasive effects of iPA at all 
concentrations, allowing wound closure within 24 h and the invasion of the 
Matrigel coating (Fig. 15A–C). Afterward, iPA was tested for its effect on 
the morphologic differentiation of endothelial cells into tube-like 
structures, another endothelial cell property that is fundamental to 
angiogenesis. A 2-dimensional tube formation assay was performed by 
plating endothelial cells into a Matrigel coat, which replicates in vitro the 
conditions that best mimic the microenvironment that allows the 
differentiation of the capillaries. The angiogenic response was assessed by 
quantification of the capillary network that was formed in a 2-dimensional 
matrix of Matrigel in the presence of complete proangiogenic medium after 
5 h. 
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Figure 15. iPA inhibited endothelial cell migration, invasion and capillary network 
formation. A) Confluent endothelial cell monolayers were treated with iPA (2.5–10 µM), 
with or without pretreatment with 5-Itu (30 nM, 30 min), and wounded with a 200 µl tip, 
as described in Materials and Methods. Image of wound closure are representative, 
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captured within 24 h by a time-lapse video microscopy system (×10; AF6000 LX; Leica). 
White dotted lines mark the wound area. B) Width of each wound, calculated from images 
at different time points (0, 6, 12, and 24 h) measured by ImageJ 1.45 software. Degree of 
wound regeneration was calculated as the percentage of the remaining cell-free area 
compared to the vehicle control or respective treatment without 5-Itu, expressed as means 
± SD of 2 independent experiments in triplicate., ***P < 0.001 vs. control or treatment 
without 5-Itu; ANOVA. C) Matrigel invasion assay in transwells was performed as 
described in Materials and Methods. Endothelial cells were treated with iPA (1–10 µM), 
with or without 5-Itu pretreatment (30 nM, 30 min). Graph reports the number of invading 
cells during 18 h, expressed as means ± SD of 3 experiments in triplicate. **P < 0.01, 
***P < 0.001 vs. control [invading cells in the absence of chemotactic factors (cells 
moved by chemokinesis), or respective treatment without 5-Itu]; ANOVA. D) For the 
capillary-like tube formation assay, endothelial cells were treated with iPA (2.5–10 µM), 
with or without 5-Itu pretreatment (30 nM, 30 min), and seeded on a thick layer of 
Matrigel. Images are representative of 3 experiments in triplicate. E) Number of 
intersections analyzed by ImageJ 1.45 software, expressed as means ± SD of 3 
independent experiments in triplicate. *P < 0.05 vs. control or respective treatment 
without 5-Itu; ANOVA. 
 
The images show that iPA inhibited the formation of the capillary network 
in a dose-dependent manner. In 5-Itu-pretreated endothelial cells, there was 
a complete reversal of the anti-angiogenic effects of iPA at 2.5 and 5 µM, 
because the capillary network was comparable to that of the control. With 
10 µM iPA, there was no capillary network, showing that 5-Itu 
pretreatment did not reverse the effect of specific inhibition of the capillary 
network formation exercised by iPA, but only the effect on cell viability. 
Indeed, endothelial cells were present in the Matrigel matrix, but they did 




4.7 iPA inhibits angiogenesis in vivo 
The antiangiogenic effect displayed by iPA in vitro prompted us to confirm 
its activity in vivo by the Matrigel plug assay. FGF2 administered in the 
Matrigel plugs induced a consistent angiogenic process, as demonstrated 
by expression of the CD31 endothelial marker, measured both by 
quantitative RT-PCR (Fig. 16A) and immunofluorescence (Fig. 16B). 
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Accordingly, treatment with iPA significantly reduced the 
neovascularization process induced by FGF2, whereas any inhibitory effect 
was observed when the isoprenoid IPP was added to the plugs as the 
negative control.  
 
Figure 16. iPA inhibited angiogenesis in vivo. A) Matrigel plugs containing 27 nM of 
FGF2/plug (shaded bars) were added with vehicle, 5 µM/plug of iPA, 5 µM/plug of IPP, 
or 30 nM 5-Itu   5 µM/plug of iPA and implanted subcutaneously in mice. After 1 week, 
the plugs were assessed for CD31 mRNA expression levels by RT-qPCR, and data were 
normalized to hGAPDH. Data are expressed as means ± se of 6–8 plugs/group. *P < 0.05; 
ANOVA. B) For immunofluorescence, 5 µm sections were stained with anti-CD31 
antibody; CD31
+
 blood vessels developed in Matrigel plugs containing different 
treatments are visualized in red. Micrographs are representative (×200). 
 
In keeping with our in vitro observations, the addition of 5-Itu to iPA 
abolished the inhibitory effect displayed by iPA alone. Of note, no 
significant pro- or antiangiogenic effect was observed when treatments 
were added in the absence of FGF (Fig. 16A, solid bars).  
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4.8 iPA inhibits angiogenic phenotype of melanoma cells 
To better understand the effects of iPA on tumor angiogenesis process, 
which provides necessary oxygen and nutrients for the tumor, we used 
A375 human melanoma cells, well known for their highly angiogenic 
phenotype. 
First of all, we evaluated endothelial cells viability when co-coltured with 
melanoma cells pre-treated for 24 h with increasing concentrations of iPA 
(1-10 μM). The results in Figure 13 show that iPA treatment (from 2.5 to 
10 μM) was able to affect the angiogenic phenotype of melanoma A375 
cells, significantly inhibiting the viability of endothelial cells. 
 
Figure 17. iPA treated-melanoma cells inhibited endothelial cells viability. The 
histogram shows the inhibition of endothelial cells viability after 24 h of co-culture with 
melanoma cells previously treated for 24 h with increasing concentrations of iPA (from 1 
to 10 µM), evaluated by quantitative detection of absorbance intensity (570 nm) of crystal 
violet solubilized in acetic acid. Results are representative of two independent 
experiments performed in duplicate. Mean±SD is shown (ANOVA, ***P<0.001 vs 
endothelial cells untreated). 
 
4.9 iPA inhibits melanoma cells proliferation and colony formation 
Then, we assessed the direct effect of iPA on A375 melanoma cells 
biological functions. The treatment of A375 for 24, 48 and 72 hours with 
increasing concentrations of iPA (from 1.25 μM to 40 μM) inhibited the 
proliferation after 24 h of treatment only at highest concentrations used (20 
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and 40 μM), whilst after 48 and 72 hours iPA was able to block the 
proliferation already at 5 μM. In order to investigate the mechanism 
through which iPA exerted its inhibitory effects also in melanoma cells and 
to confirm that phosphorylation in position 5'- by ADK was indispensable 
for its action, we pre-treated melanoma cells with ADK specific inhibitor, 
5-Itu (30 nM, 30 min). According with the mechanism of action of iPA in 
endothelial cells model, the pre-treatment with 5-Itu (Fig. 18A-C, gray 
bars) reverted the effects of iPA on melanoma cells proliferation at all the 
concentrations and time points, confirming that phosphorylation of iPA in 
C5 by ADK is crucial also to its anti-tumor activity and that the active 
metabolite is precisely N6-isopentenyladenosine 5'-monophosphate 
(iPAMP).  
 
Figure 18. iPA inhibited melanoma cells proliferation and colony formation. A-C) 
Histograms show the inhibition of proliferation of melanoma cells, pre-treated (shaded 
bars) or not (solid bars) with the ADK inhibitor 5-Itu (30 nM, 30 min), performed by 
BrdU proliferation assay for 24 h (A) 48 h (B) and 72 h (C). Results (A-C) are expressed 
as mean±SD of one experiment performed in triplicate. D) The image shows 
representative pictures of melanoma cells after ten days of treatment with increasing 
concentrations of iPA (1-10 μM) pre-treated or not with 5-Itu (30 nM, 30 min). Colonies 
have been fixed, stained with crystal violet and photographed. Experiment was performed 
in duplicate. (ANOVA, *P<0.05, **P<0.01, ***P<0.001 vs control, represented by cells 
untreated or treated without 5-Itu). 
Moreover, to test iPA sensitivity on melanoma cells proliferation after a 
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prolonged in vitro exposure, we also performed human tumor clonogenic 
assay. Cells were treated at time 0 h with increasing concentrations of iPA 
alone (1-10 μM) with or without the pre-treatement with 5-Itu (30 nM, 30 
min) and were monitored for ten days. Results in Figure 18D show the 
ability of iPA to inhibit colony formation in a concentration-related 
manner, reducing the number and dimension of colonies. Moreover, at 
higher concentrations (2.5-10 μM) iPA did not allow the formation of any 
colony, whereas when cells were treated with iPA 1 μM only the 
dimensions of colonies were reduced. Once again, the pre-treatment with 
5-Itu completely reverted the inhibitory effect of iPA on colony formation 
(Fig. 18D). 
 
4.10 iPA induces a G1-phase stasis and apoptosis in melanoma cells 
To analyze the nature of the anti-proliferative action of iPA, we evaluated 
its effect on melanoma cells distribution during cell cycle by flow 
cytometric analysis. Thus, melanoma cells were treated with increasing 
concentrations of iPA alone (from 1 to 10 μM) or following 5-Itu pre-
treatment (30 nM, 30 min) for 24, 48 and 72 hours. Subpopulations of G1- 
and S/G2M-phase were then analyzed. As shown by quantitative analysis, 
iPA blocked proliferation of melanoma cells in G1 phase of cell cycle 
already after 24 h of treatment at the highest concentration tested and this 
effect was potentiated after 48 hours of treatment (Fig. 19A). After 72 h of 
treatment the G1 phase stasis was no more relevant.  
In order to evaluate whether the block of cell cycle correlated with the 
induction of apoptosis, we analyzed the percentage of apoptotic cells, by 
staining with Annexin V and propidium iodide (PI) in response to various 
iPA concentrations in human melanoma cells, with or without 5-Itu pre-
treatment (Fig. 19B). Data obtained show that already after 24 hours of 
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treatment iPA exerted a slight induction of apoptosis, while this pro-
apoptotic effect became substantially clear after 48 and even more after 72 
hours of treatment with increasing concentrantions of iPA (1-10 μM). 
Indeed, the percentage of apoptotic cells after 24 h was about 15%, after 48 
h about 30% and finally after 72 h of treatment with iPA 10 M was about 
70%. As expected, 5-Itu reverted the effect on the cell cycle arrest and the 
pro-apoptotic action of iPA, highlighting that the active form of iPA is 
iPAMP, as well as in endothelial cells. 
 
 
Figure 19. iPA induced a G1-phase stasis and apoptosis in melanoma cells. A) The 
histograms report the quantitative analysis of melanoma cells in the different phases of 
cell cycle following treatment with iPA (from 1 to 10 µM) with or without pre-treatment 
with 5-Itu (30 nM, 30 min) in time course (24, 48 and 72 h), expressed as percentage. B) 
The histrograms report the quantitative analysis of melanoma cells Annexin V positive 
and Annexin V/PI double positive with or without 5-Itu pre-treatment (30 nM, 30 min) in 
time course (24, 48 and 72 h). Results are representative of two independent experiments. 
Mean±SD is reported. (ANOVA, *P<0.05, **P<0.01, ***P<0.001 vs cells untreated or 
cells treated with 5-Itu). 
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4.11 iPA induces AMPK-dependent activation of autophagy in 
melanoma cells 
  
To corroborate the parallelism between endothelial system and cancer 
model, the activity of the energy sensor AMPK was analyzed. After 24 
hours of treatment, iPA was able to induce the phosphorylation of AMPK-
α catalytic subunit also in melanoma cells (Fig. 20). Since in a great 
number of cancer models the AMPK pathway appears to be involved in 
autophagy, we also investigated this possible correlation. To this end, 




Figure 20. iPA activated AMPK inducing its phosphorylation. Increase in AMPK 
activity was analyzed by western blot. Melanoma cells, grown in serum containing 
medium, were treated with iPA at the indicated concentrations for 24 h. Tubulin served as 
the loading control. Data are representative of two different experiments with similar 
results. Histogram (right panel) reports the results of the quantitative analysis (arbitrary 
units, pAMPK/ AMPK/ tubulin) as mean ± SD of two independent experiments. 
(ANOVA, *P<0.05 vs. control). 
 
The acidotropic dye LysoTracker Red DND-99, a probe which exhibits 
fluorescence that is largely independent of pH, was diluted in PBS. Red 
lysosomal fluorescence of 10,000 cells per sample was determined by flow 
cytometry using the FL3 channel. The histograms clearly show the time- 
and concentration- dependent autophagic flux (Fig. 21A). Already after 24 
hours of treatment with iPA there was an evident trend of increasing in the 
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acidic flux due to autophagolysosome formation, peculiar of autophagic 
dynamic process. The MFI value increased in a dose- and time-dependent 
manner. Interestingly, after 72 h of treatment was visible also a 
characteristic peak of dead cells (see above), indicating that the autophagic 
process in this case is not a protective mechanism but on the contrary a 
preliminary step to cell death induction. 
In order to detect the acidic compartment, we also used the lysosomotropic 
agent acridine orange, a weak base that moves freely across biological 
membranes when uncharged. Its protonated form accumulates in acidic 
compartments, where it forms aggregates that fluoresce bright red. 
Through this latter assay iPA appeared an autophagy activator already after 
24 h of treatment until 72 h. This pro-autophagic effect was completely 
reverted by 5-Itu pre-treatment (Fig. 21B). 
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Figure 21. iPA induced autophagy in melanoma cells. (A) Melanoma cells were treated 
with increasing concentrations of iPA (from 1 to 10 µM) for 24, 48 and 72 h. Cells in 
suspension (1×10
4
) were labeled with lysotracker-red (70 nM) and then activity of 
lysosomal acid phosphate of melanoma cells was analyzed by flow cytometry 
(excitation/emission, 577/590 nm). In the left panel the most representative images of 
flow cytometer analysis are shown, whilst in the right panel the histrograms show the 
quantitative analysis of two independent experiments in the three different time points. (B) 
Melanoma cells were treated with increasing concentrations of iPA (from 1 to 10 µM) 
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with or without 5-Itu pre-treatment (30 nM, 30 min) for 24, 48 and 72 h. Cells (1×10
4
) 
were labeled with acridine orange (10 µg/mL) for 15 min at 37°C and quantified using 
flow cytometry. FL1-H indicates green color intensity (cytoplasm and nucleus), whereas 
FL3-H shows red color intensity (acidic vesicular organelles, AVO, peculiar of autophagy 
process). In the left panel the most representative images of flow cytometer analysis are 
shown, whilst in the right panel the histrograms show the quantitative analysis of three 
independent experiments in the different time points. Data were analyzed by FlowJo 
software version 8.2 (Tree Star, Inc., Ashland, OR, USA). The histograms (right panels) 
report the quantitative analysis (arbitrary units) expressed as mean±SD of two (A) or three 
(B) independent experiments with similar results (ANOVA, **P<0.01, ***P<0.001 vs 
control). 
 
4.12 iPA activates autophagy and apoptosis pathways to induce cell 
death in a coordinated and cooperative manner 
Since autophagy can act as an apoptosis-alternative pathway to induce cell 
death or act together with apoptosis as a combined mechanism for cell 
death, the correlation between these mechanisms was analyzed. Levels of 
peculiar proteins involved in both the processes were evaluated by western 
blot. During autophagy, LC3-I is converted to LC3-II through the Atg4-
dependent insertion of a phosphoethanolamine moiety and recruited into 
the membrane of the forming phagophore, a double membrane required for 
the recycling of protein aggregates and organelles. To analyze the 
relationships between apoptosis and autophagy in melanoma cell death, we 
treated cells with increasing concentrations of iPA (from 1 to 10 μM) for 
24h and 48 h. The expression of the peculiar autophagic protein, LC3-II, 
resulted increased starting from 24 h and remained augmented until 48 h of 
treatment with iPA (Fig. 22). The activation of the intrinsic apoptosis 
pathway was monitored by the analysis of the caspase cascade. Caspase-9 
activation, started from 24h (Fig. 22A), followed by caspase-3 activation 
and resulted in DNA repair enzyme poly (ADP-ribose) polymerase 
(PARP) cleavage (Fig. 22B), that finally leads to apoptotic cell death. 
Indeed, as shown in Figure 22B, a clear activation of caspase-3 was 
detected, followed by PARP cleavage that was significantly increased after 
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48 h of treatment with 5 and 10 μM iPA (Fig. 22B). 
 
Figure 22. iPA activates autophagy and apoptosis pathways to induce cell death in a 
coordinated and cooperative manner. Melanoma cells were treated with iPA at the 
indicated concentrations for 24 h (A) and 48 h (B). Increase of the autophagic marker 
LC3B (A and B) that leads to the activation of the intrinsic apoptosis pathway by 
expression of cleaved caspase 9 (A) and subsequently the increase of expression of 
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cleaved caspase 3 (B) and finally cleaved PARP (B), were analyzed by western blot. 
Tubulin serves as loading control. The data shown are representative of two experiments. 
The histograms (right panels) report the quantitative analysis (arbitrary units) expressed 
as mean±SD of two independent experiments with similar results (ANOVA, *P<0.05, 
**P<0.01, ***P<0.001 vs control).  
 
  
4.13 iPA selectively expands NK cells in human primary PBMCs 
culture 
Since immune-surveillance plays a role in control of tumor development 
and a study published almost 50 years ago suggested that iPA could affect 
mitosis of the phytohemagglutinin-stimulated human lymphocytes (Gallo 
et al., 1969), we asked which specific lymphocyte cell population was 
affected by the iPA ‘mitogenic’ capacity. We then analyzed the expansion 
of CFSE labeled unfractionated PBMCs stimulated with IL-2 alone (100 
U/mL) or in combination with iPA at selected concentrations, ranging from 
0.1 to 1μM. The choice of these specific concentrations was due to 
previously observations in which the addition of iPA at a concentration 
above 10
-6
 molar resulted in the inhibition of mitosis of 





 molar) had a stimulatory effect (Gallo et al., 1969). 
As highlighted in flow cytometric analysis of CFSE dye-dilution (Fig. 
23A), after a 10-day culture in the presence of IL-2 and iPA, a slight but 
statistically significant expansion of NK cells (82.27±2.3%; p<0.05, iPA 
0.1 μM and 79.1 ±3.4%; p<0.05, iPA 1 μM) was observed in comparison 
to IL-2 alone (73.7±3.8%) with no effects on other lymphocyte 
subpopulations like T and NKT cells or B cells (data not shown). Of note, 
a similar synergistic effect could not be observed in PBMCs treated with 
the well-known isoprenoid intermediate IPP or with the purine nucleoside 
adenosine (data not shown). 
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4.14 iPA directly stimulates human purified NK cells 
These first evidence prompted us to investigate if iPA directly affects NK 
cell functions or if other cells and/or soluble mediators are required for 
achieving this effect. NK cells reside in the skin (Luci et al., 2009), thus 
melanocytes and neoplastic cells are susceptible to NK cell recognition 
from early stages of dysregulation. Understanding how NK cells migrate 
into the tumor microenvironment is important to redirect NK cells to the 
tumor in the therapeutic setting. For this purpose, we evaluated the effects 
on human purified NK cells of 48h-treatment with iPA alone in the 
absence of cytokine support. Interestingly, iPA 0.1 μM and, to a lesser 
extent, iPA 1 μM activated human resting NK cells, as measured by a 
significant increase in the percentage of CD69 positive NK cells (Fig. 23B) 
(25 ±3.9%; p<0.01, iPA 0.1 μM vs 16.3±2.9 of NK alone and 23.6±2.9%; 
p<0.01, iPA 1 μM vs 16.3±2.9 of resting NK alone). 
 
Chapter4                                                                                          RESULTS 
74 
 
Figure 23. iPA selectively expanded and directly activated NK cells in human 
primary PBMCs cultures . (A) Cultured CFSE-labeled human PBMCs stimulated with 
IL-2 (100U/mL) alone or in combination with iPA at the indicated concentrations were 
analyzed for expansion (CFSE dye dilution) by flow cytometry. Data in A are gated to 
show CFSE staining on viable CD3+ T cells or alternatively on viable CD56+CD3- NK 
cells. Mean percent ± SD of dividing cells of five different donors is reported in 
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histograms. (B) Human purified CD56+CD3- NK cells cultured in complete medium with 
or without iPA for 48 h were stained using anti-CD3, anti-CD69 and anti-CD56 mAbs and 
analyzed by flow cytometry. A representative dot plot (left) is presented. Bars graph 
(right) report the percentage ± SD of CD69+ of CD56+CD3- gated NK cells from five 
independent experiments using different donors. Statistical analysis is indicated 
(ANOVA, **P<0.01 compared with resting NK cells cultured in medium alone). (C) 
Representative example (left) for cytofluorimetric histogram profiles of purified NK cells 
maintained in culture for 48 h with iPA (empty profiles) or without iPA (gray profiles). 
Bars graph (right) reports mean and SD of the MFI for each marker in CD56+CD3- gated 
NK. Results are representative of four independent experiments using different donors. 
(ANOVA, *P<0.05, **P<0.01 and ***P<0.001 compared with resting NK cells cultured 
in medium alone). (D) Human purified CD56+CD3- NK cells cultured in complete 
medium alone (none; circles) or treated with the selected iPA concentrations (iPA 0.1 μM, 
squares and iPA 1 μM, triangles) for 48 h were then tested for cytotoxic activity against 
K562 cells. E:T ratios are indicated. Duration of the assay was 4 h. Results were 
expressed as the mean ± SD of 4 independent experiments. All pairwise comparisons are 
statistically significant between treatment groups (ANOVA, **P<0.01 and ***P< 0.001). 
(E) ELISA IFN-γ assay of purified NK cells cultured with complete medium alone or in 
combination with increasing concentrations of iPA for 48 h, before being incubated with 
K562 for additional 6 h at 37°C. At the end of the co-incubation period, supernatants were 
harvested and the concentrations of IFN-γ were determined. Values represent mean ± SD 
of 3 different donors. Selected statistical analyses are indicated. (ANOVA, *P<0.05, 
compared with resting NK cells cultured in medium alone). 
 
Moreover, in the same experimental condition, cytofluorimetric analysis 
revealed that in the presence of iPA, NK cells displayed a sharp and 
significant up-regulation of NKp46 and NKG2D activating receptors while 
surface expression of NKp30 and NKp44 was not affected (Fig. 23C). 
Accordingly, this phenotype correlates with a significant greater 
cytotoxicity exerted by iPA-treated NK cells against the classic K562 
tumor target (p<0.001, iPA 0.1 μM vs resting NK alone and p<0.001, iPA 
1 μM vs resting NK alone) measured by using the fluorescent carboxy-
Fluorescein Diacetate c’FDA NK cytotoxic assay, as described in 
Materials and Methods (Fig. 23D). Of note, iPA did not induce IFN-γ 
secretion in treated NK cells upon K562 target cell encounter (Fig. 23E), 
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4.15 iPA synergizes with IL-2 for the proliferation and activation 
status of human purified NK cells 
Because usually NK cells do not survive for a long period of time without 
cytokine support (Taguchi et al., 2004) and, most importantly, to reproduce 
an experimental setting more similar to in vivo microenvironment where 
both proinflammatory cytokines and target cells may coexist, we analyzed 
the iPA immunostimulatory properties on IL-2 stimulated NK cells and 
where indicated, in presence or absence of the classical NK target K562 
erythroleukemia cell line. 
First we tested the effects of iPA on NK cells proliferative response to IL-
2, isolating CD56+CD3-NK cells from healthy donors by 
immunomagnetic separation. The NK cell proliferation index was then 
measured at different time intervals (at days 3, 8 and 10 of culture) by 
CFSE dye-dilution. In line with the results obtained with unpurified PBMC 
cultures, the treatment with iPA (0.1 μM and 1 μM) caused a significant 
increase in IL-2 driven purified NK cell expansion at day 10 of culture 
(P<0.001) (Figg. 24A, B). Then, to fully measure NK activity in response 
to iPA, we performed a parallel assessment of the cell surface up-
regulation of CD69, a molecule associated with NK cell early activation, 
after co-incubation with K562 (Dons’koi et al., 2011). To this end, human 
purified NK cells were co-treated for 48 hours with the selected 
concentrations of iPA plus IL-2. The expression of CD69 was then 
evaluated after co-incubation with K562 at 1:2 effector:target (E:T) ratio 
for additional 6 hours. As shown in figure 24C, IL-2 primed NK cells 
cultured with media alone express low levels of CD69 (8%). In contrast, 
after incubating with K562, 59% of IL-2 treated NK cells express CD69 on 
their surface and the co-treatment with iPA 0.1 and 1 μM further increases 
the expression of CD69 on NK cells to 65% and 69%, respectively. These 
results clearly indicate that iPA synergizes with IL-2 for the proliferation 
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Figure 24. iPA positively affected the proliferation of IL-2 stimulated NK cells and 
CD69 surface expression. (A) Human purified CD56+CD3- NK cells were labeled with 
CFSE and cultured with medium containing IL-2 (100U/mL) with or without iPA at the 
indicated concentrations. After 3,8 and 10 days cells were collected and analyzed by flow 
cytometry. Panel A shows representative data of the CFSE fluorescence intensity and 
proliferation kinetics model of NK cells maintained in culture for 10 days. The indicated 
numerical values for proportions of proliferated cells among NK cell population were 
calculated by using ModFit LT software. (B) Composite data from three different donors 
showing means ± SD for rates of dividing NK cells in the same experimental conditions 
as in A. All pairwise comparisons are statistically significant between treatment groups 
(ANOVA, **P< 0.01 and ***P< 0.001). (C) NK cells were cultured for 48 h in medium 
supplemented with IL-2 (100U/mL) with or without different concentrations of iPA, then 
washed and incubated with K562 at 1:2 ratio for 6 h. Therefore cells were collected and 
analyzed by flow cytometry for the cell surface expression of CD69 on gated CD3-CD56+ 
NK cells. The basal activation of IL-2 primed NK cells without K562 is also reported. The 
1 donor-representative dot plots with mean percent ± SD from five separate experiments 
are presented. 
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4.16 Stimulatory effect of iPA on NK cell-mediated antitumor 
cytotoxicity and on the surface expression of NKp30 
K562-induced CD69 expression displays NK lymphocyte functional 
condition that is associated with their cytotoxic function (Dons’koi et al., 
2011). To determine whether iPA stimulation of IL-2 primed NK cells 
enhances their cytolytic activity, we tested treated and untreated NK cells 
against the NK susceptible target cell line K562. To this end, NK cells 
were stimulated with IL-2 in the presence or absence of increasing doses of 
iPA (from 0.1 to 1 μM). After 48 hours of culture, NK cells were washed 





 labeled dead target cells revealed that IL-2 primed 
NK cells displayed intermediate levels of cytotoxicity with respect to the 
higher efficiency of killing by IL-2 primed NK cells co-treated with iPA 
0.1 μM and with iPA 1 μM (p<0.01, iPA 0.1 μM vs IL-2 alone and p<0.01, 
iPA 1 μM vs IL-2 alone) (Fig. 25A). To confirm the lytic potential of NK 
cells in vitro, we used another parameter of NK cell activation, which is 
the expression of the lysosomal-associated membrane protein-1 (LAMP-1, 
also known as CD107a) (Alter et al., 2004). After short term co-cultures at 
1:1 E:T ratio, cells that stain positive for CD107a have degranulated and 
can be readily enumerated by flow cytometry. Consistent with previous 
data, the highly susceptible K562 tumor cell lines induced a strong 
CD107a expression in IL-2 primed NK cells (consistently greater than 
30%) but, remarkably, in NK cells co-treated with 0.1 μM and 1 μM doses 
of iPA, CD107a expression, in terms of percentage of positive cells, was 
higher (48.2 ± 6.2 %; p<0.05, iPA 0.1 μM vs 28.4±5.6 of IL-2 alone and 
49.6±6.1%; p<0.05, iPA 1 μM vs 28.4±5.6 of IL-2 alone) (Fig. 25B). 
Several structurally different activating receptors are involved in NK cell 
mediated cytotoxicity (Moretta et al., 2001; Alter et al., 2004). After 48 
hours of culture, cytofluorimetric analysis revealed that in presence of iPA 
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0.1 μM and 1 μM, NK cells that had been stimulated with IL-2, displayed a 
significantly sharp upregulation of NKp30 (p<0.001, iPA 0,1 μM vs IL-2 
alone and p<0.001, iPA 1 μM vs IL-2 alone) and to a minor extent of 
NKG2D, even though this is observed only in response to the 
concentration of iPA of 0.1 μM (p<0.05, iPA 0.1 μM vs IL-2 alone). On 
the other hand, surface expression of NKp44 and NKp46 was not 
significantly affected (Fig. 25C). 
 
 
Figure 25. iPA potentiated cytotoxic effector fuctions of IL-2 primed NK cells. 
Cytotoxic activity of IL-2 primed NK cells or IL-2/iPA co-treated NK cells vs K562 was 
assessed by flow cytometry. Percent of specific lysis was calculated. (A) A representative 
histogram profile (upper panel) of K562 incubated with IL- 2 treated NK or alternatively 
with NK cells treated with increasing doses of iPA at 1:1 E:T ratio. Each sample was then 
tested in triplicate at three E:T ratios. Results (lower panel) are expressed as mean ± SD 
of 4 independent experiments. All pairwise comparisons are statistically significant 
between treatment groups (ANOVA, **P<0.01 and ***P< 0.001). (B) NK cells were 
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treated with IL-2 alone or in combinations with increasing doses of iPA for 48 h, before 
being tested for their ability to degranulate in response to K562. Bars graph report the 
percentage of CD107a+ of CD56+CD3- gated NK. Results shown are representative of 
three independent experiments (ANOVA, *P<0.05 compared with NK cells cultured in 
presence of IL-2 alone). (C) Surface expression of NKp30, NKp44, NKp46 or NKG2D 
was monitored by FACS using purified NK cells cultured for 48 h with IL-2 (100U/mL) 
in the presence or absence of increasing concentrations of iPA. Bars graph reports mean 
and SD of the MFI for each marker in CD56+CD3- gated NK cells. Results are 
representative of 4 independent experiments using different donors. (ANOVA, *P<0.05, 
**P<0.01 and ***P<0.001 compared with NK cells cultured in presence of IL-2 alone). 
 
 
4.17 Cytokines and chemokines secretion profile of iPA treated-NK 
cells upon interaction with K562 cells 
When an NK cell encounters its cognate ligand on a target cell, it mediates 
cytotoxicity and besides its ability to secrete the effector cytokine, IFN-γ 
(Lanier et al., 2005), it has the capacity to produce a variety of other 
cytokines, like tumor necrosis factor-α (TNF-α) and chemokines 
(CCL3/MIP-1α and CCL5/RANTES) (Vivier et al., 2008; Fauriat et al., 
2010). We then evaluated the ability of iPA-treated NK cells to release 
these soluble factors, with particular focus on early time interval (6 hours) 
upon K562 target cell recognition (Fauriat et al., 2010). Therefore, NK 
cells from healthy donors were maintained in culture medium 
supplemented with IL-2 (100 U/mL) in the presence or absence of 
increasing doses of iPA. After 48 hours, NK cells were washed and 
incubated alone or with K562 for 6 hours. Supernatants were harvested and 
the concentration of different released factors was determined by a 
multiplex immunoassay (Fig. 26). As expected, stimulation of NK cells by 
K562 induced IFN-γ and TNF-α secretion as well as an ample secretion of 
CCL3 and CCL5 by IL-2 primed NK cells. Notably, the treatment with 
iPA 0.1 μM resulted in a significant increase in the secretion of all soluble 
factors measured (P<0.05 for IFN-γ, P<0.001 for TNF-α, CCL3 and 
CCL5), instead iPA 1 μM positively affected only the secretion of the 
effector cytokines IFN-γ and TNF-α (P<0.05), with no effects on the 
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chemokines, CCL5 and CCL3, whose secretion is particularly dependent 
on NKG2D engagement that iPA 1 μM is not able to upregulate, like iPA 
0.1 μM does (Fauriat et al., 2010) .Thus, the costimulatory effects of IL-2 
primed NK cells by the selected doses of iPA are not confined only to 
cytotoxic effector mechanisms, but also involve the release of cytokines 
and chemokines by which NK cells can instruct and shape adaptive 
immune response (Vivier et al., 2008). 
 
Figure 26. Cytokines and chemokines secretion profiles of IL-2 plus iPA-treated NK 
cells upon target cell recognition. Purified NK cells were treated with IL-2 alone or in 
combination with the indicated concentrations of iPA for 48 h, before being incubated 
alone or with K562 for 6 h at 37°C. Supernatants were harvested and the concentrations of 
cytokines and chemokines were determined by a multiplex immunoassay that 
concurrently detect multiple analytes in a single sample by Luminex Platform. Values 
represent mean ± SD of 3 different donors. Selected statistical analyses are indicated. 
(ANOVA, *P<0.05, **P<0.01 and ***P<0.001 compared with NK cells cultured in 
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4.18 MAPK signal transduction is uniquely modulated by iPA plus 
IL-2 stimulation 
To gain insight into the molecular bases of the synergistic actions of IL-2 
and iPA on human primary NK cells, we next investigated whether and in 
which way the IL-2 signal transduction pathways were affected by 
increasing doses of iPA, with particular attention to JAK-STAT and 
MAPK signaling pathways, primarily used by IL-2 to drive cytokine 
expression and lytic granule exocytosis and cytotoxicity (Liu et al., 2012; 
Li et al., 2008; Yu et al., 2000; Chiossone et al., 2007). As shown in Figure 
27A, ERK was phosphorylated in response to IL-2 stimulation. However, 
iPA 0.1 μM and iPA 1 μM led to significant greater levels of 
phosphorylated ERK compared with the effect observed in response to IL-
2 alone (p<0.01, iPA 0.1 μM vs IL-2 alone and p<0.05, iPA 1 μM vs IL-2 
alone). On the other hand, p38 phosphorylation was not affected by iPA 
treatment. Moreover, in contrast to the findings in the ERK/MAPK 
pathway, no differences were observed in the activation of STAT signal 
transduction pathways. Specifically, there was no evidence for enhanced 
tyrosine phosphorylation of STAT5 in response to co-stimulation with the 
indicated doses of iPA, compared with the effect observed in response to 
IL-2 alone. Similarly, the combination of iPA low doses plus IL-2 did not 
alter signaling intermediates in the PI3K pathway, compared to stimulation 
with IL-2 alone (data not shown). It is of note that kinetic studies (Fig. 
27B) revealed that the enhancement of ERK activation by iPA co-treatment 
started 30 minutes after the exposure of cells to iPA when the stimulatory 
effect of IL-2 alone was not yet evident. This co-stimulatory effect, that 
was still observed after 3 hours, only occurred at the highest iPA 
concentration (p<0.01, iPA 1 μM vs IL-2 alone at 1 hour and p<0.05, iPA 1 
μM vs IL-2 alone at 3 hours) while iPA 0.1 μM caused a slight increase in 
the levels of phosphorylated ERK species that did not reach statistical 
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significance before 18 hours of treatment (Fig. 27A). These data support 
the notion of a long-lasting effect of iPA and are compatible with its 
sustained action over the time, on different aspects of NK cell biology. 
 
Figure 27. Molecular analysis of the iPA-mediated effects on NK cells functions: 
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evidence for an exclusive modulation of MAPK. (A) Purified NK cells were treated 
with IL-2 alone or in combination with the indicated concentrations of iPA for 18 h 
(overnight). Representative blots (left) and quantitative/densitometric analysis (arbitrary 
units) (right) of results from 4 different experiments are shown. All the relative protein 
levels were calculated by normalizing the levels of these proteins with the levels of β-actin 
which serves as internal loading control. The relative levels of specific phosphorylation of 
ERK (p/ERK), p38 (p/p38) and STAT5 (p/STAT5) were then calculated by normalizing 
the levels of phosphorylated forms with the levels of their cognate proteins. All 4 
experiments were performed in duplicate with similar results (ANOVA, *P<0.05 and **P 
<0.01). (B) Representative western blot (upper panel) and quantitative/densitometric 
analysis (arbitrary units) (lower panel) of results from 3 different experiments conducted 
on purified NK cells stimulated with IL-2 alone or in combination with the indicated 
concentrations of iPA at different time points are shown. All 3 experiments were 
performed with similar results (ANOVA, *P<0.05 and **P <0.01). 
  
4.19 iPA–mediated effects on IL2- stimulated NK cells are MAPK 
dependent 
Because iPA appeared to increase ERK activation, we further characterized 
the functional correlates of this finding. Figure 25 shows combined data 
from experiments conducted in fresh primary human NK cells pretreated 
for 30 min with 10 μM UO-126, a small molecule MEK1/2- specific 
inhibitor and then put in culture with IL-2 with or without iPA for the 
indicated time points. We confirmed that NK-cell activation in response to 
IL-2 alone, both in terms of upregulation of CD69 (Fig. 28A) and NKp30 
activating receptor (Fig. 28B), as well as secretion of IFN-γ (Fig. 28C) and 
cytotoxic potential against K562 (Fig. 28D), were dependent on MAPK 
signaling, since the presence of the MAPK inhibitor impaired the NK 
responses (Yu et al., 2000). Interestingly, the MEK inhibitor also had a 
profound effect in inhibiting the NK cell activation in response to the 
synergic action of iPA 0.1 and 1 μM plus IL-2 (P<0.001), but to higher 
extent than it can do in NK cells cultured with IL-2 alone. 
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Figure 28. The effects on NK cells by iPA plus IL-2 were inhibited by UO-126. Before 
the treatment with IL2 ± iPA at different concentrations, purified NK cells were pretreated 
with UO- 126 (10 μM) for 30 min. They were then tested for the different assays in the 
same experimental conditions described above. Data are expressed as means ± SD of 
experiments performed on 3 different donors. Selected statistical analyses are indicated. 
(ANOVA, **P <0.01 and ***P<0.001 compared with NK cells cultured with IL-2 alone 
in presence or absence of the inhibitor). 
 
 
4.20 Analysis of the mechanism underlying the stimulatory effect of 
iPA: a role for the farnesyl diphosphate synthase 
Finally, we started to investigate the molecular mechanism explaining, at 
least in part, the observed enhancement in NK cell functions by iPA. 
Activation of ERK follows a highly conserved set of molecular events and 
Ras protein is an essential factor in the regulation of MAPK (Mor and 
Philips, 2006). So, we decided to verify the effects of iPA costimulation on 
Ras activity. IL-2 stimulation induced Ras activation but the co-treatment 
with iPA (only at 1 μM) led to greater levels of bound Ras-GTP, the active 
form of Ras, confirming the synergy between IL-2 and iPA low doses (Fig. 
29A). Ras needs post-translational modification (generally, farnesyl and 
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palmitoyl lipidation) for membrane binding and activation (Ahearn et al, 
2011; Gazzerro et al., 2012). Our previous in vitro and in vivo findings 
highlighted a role for iPA in modulating the expression and activity of the 
farnesyl diphosphate synthase (FDPS) an enzyme of the isoprenoid 
pathway, crucial in generating lipids moieties used for the activity of the 
small GTP-ase proteins (Laezza et al., 2006). In light of this, we started to 
investigate the expression and the activity of the FDPS in primary human 
NK cells treated with IL-2 in presence or absence of iPA for 24 hours. Of 
note, in Fig. 29B we documented for the first time the expression of FDPS 
in human primary NK cells and we observed that FDPS expression was 
increased in IL-2 activated NK cells co-treated with iPA 0.1 and 1 μM. In 
parallel, also the FDPS activity was found to be increased after co-
incubation with iPA, especially in response to the co-treatment with iPA 
0.1 μM (P<0.01) (Fig. 29C).  
 
Figure 29. Ras and FDPS were activated after induction of iPA-mediated response in 
NK cells. (A) Quantification of Ras activation. Purified NK cells were incubated 
overnight alone or with indicated stimuli. Cells were then lysed and subjected to pulldown 
assay with Raf-RBD-GST. The amount of precipitated Ras-GTP was determined by 
immunoblotting using pan-Ras antibody. Actin serves as loading control. The data shown 
is representative of 3 different experiments. (B) Representative blot for FDPS protein 
expression (upper panel) and quantitative analysis (arbitrary units) (lower panel) of 
results from 3 independent experiments conducted on purified NK cells incubated 
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overnight alone or with indicated stimuli are shown. Densitometric mean values of FDPS 
were normalized by β-actin expression under each treatment condition. (C) Quantification 
of FDPS enzymatic activity. Bars graph reports mean±SD of the FDPS activity. The 
experiments were performed in the same conditionsdescribed above, with NK cells 
purified from 4 different donors and similar results were obtained (ANOVA, **P<0.01 vs 
control). 
 
These experimental evidence suggest that the activation of IL-2 primed NK 
cells exerted by low concentrations of iPA appears to be due to the 
activation of the FDPS enzyme. Even if we cannot exclude the 
involvement of other signaling pathways, our first preliminary results 
reinforce the role of isoprenoids in the regulation of physiological cellular 
processes in the immune compartment. 
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In the present work, we investigated whether iPA, an end product of the 
mevalonate pathway with an isopentenyl chain linked to the nitrogen at 
position 6 of the purine base, could be considered as a potential lead 
compound for a new class of antitumoral agents. Indeed, while anticancer 
activity of iPA in vitro is well documented, iPA (i.p., 10 mg/kg) has been 
reported to exert a modest activity in vivo, probably because of its short 
plasma half-life, as happens with other nucleosides (Colombo et al., 2009). 
Anyway, it has been previously demonstrated the ability of iPA, even at 
very low doses (s.c., 0.5 mg/kg), to inhibit cancer growth also in vivo in a 
nude mouse xenograft model (Laezza et al., 2006). Probably, the reasons 
of this apparent discrepancy could be attribuited to the way of drug 
administration. In the light of this, new analogues of iPA with more 
pharmacological stability in vivo result to be necessary. 
Specifically, we evaluated if iPA could directly interfere with the 
angiogenic process, fundamental to tumor growth and progression, and 
with melanoma growth, a tumor well known for its angiogenic phenotype. 
Finally, we investigated if iPA could have also an immunomodulatory role, 
in order to provide a cooperative and multifactorial mode of action to arrest 
cancer growth. 
 
5.1 N6-isopentenyladenosine inhibits angiogenesis in vitro and in 
vivo through AMPK activation 
The antitumoral effects of iPA have already been reported (Bifulco et al., 
2008), whereas to date there was no evidence of its effects on the 
angiogenic process. In the current study, we found that iPA inhibited all 
the steps of angiogenesis. Indeed, treatment with iPA affected endothelial 
cell viability with minimal effects on quiescent cells, observable only at 
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higher concentrations. iPA strongly blocked endothelial cell proliferation 
in a concentration- and time-dependent manner (Fig. 7B-D). It is important 
to note that the antiproliferative effects of iPA can be ascribed to its 
peculiar structure, composed of the specific combination of the adenosine 
moiety and the isopentenyl chain. Indeed neither the sintetic analogues 
(Fig. 9), nor nitrogenous base adenine, nor adenine harboring the same 
modification in N6, nor yet the isopentenyl pyrophosphate resembling the 
isoprenoid chain alone affected endothelial cell proliferation (Fig. 8). As 
regard to adenosine it is well known its ability to stimulate angiogenesis in 
response to ischemic/hypoxic stress that stimulates vascular endothelial 
growth factor (VEGF) production (Auchampach, 2007). Given the 
structural similarities of iPA with adenosine, we investigated if it could act 
through specific adenosine receptors, A2A and A2B, expressed on 
endothelial cells and thightly involved with angiogenesis process. Obtained 
data exclude any interaction with adenosine receptors in endothelial cells 
since specific A2A and A2B antagonists used in pre-treatment had no 
effect on inhibitory action of iPA (Fig. 11). Given the absence of specific 
membrane receptors, the way by which iPA could enter into the cells 
remained an open question. So, we wondered whether iPA could enter into 
cells through nucleoside transporters. The passage of nucleosides across 
plasma membranes or between intracellular compartments occurs primarily 
via specialized nucleoside transporter proteins (NTs) (King et al., 2006). 
Once inside, they are activated by intracellular metabolic steps to 
triphosphate derivatives. In general, active derivatives of nucleoside 
analogues can then exert cytotoxic activity by being incorporated into and 
altering the DNA and RNA macromolecules or by interfering with various 
enzymes involved in the synthesis of nucleic acids, such as DNA 
polymerases and ribonucleotide reductase. These actions result in the 
inhibition of DNA synthesis and apoptotic cell death, as we have shown 
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with the treatment with iPA (Galmarini et al., 2002). 
Two major families of transporters, the equilibrative NTs (ENTs) and 
concentrative NTs (CNTs), have been identified by molecular cloning and 
functional expression of cDNAs encoding NT proteins from a variety of 
species, including mammals, protozoan parasites and bacteria (Kong et al., 
2004). Four human ENT and three hCNT subtypes have been identified by 
molecular cloning and functional expression. hENTs have been reported to 
mediate facilitated diffusion of nucleosides across membranes 
bidirectionally according concentration gradients, whilst uman CNTs 
transport nucleosides work against concentration gradients (Kong et al., 
2004). Dipyridamole is a well-known inhibitor of ENTs (Wang et al., 
2013). In the light of all these considerations, pre-treating endothelial cells 
with dipyridamole before iPA treatment we found that its effects were not 
abolished (Fig. 11). 
By LC-MS/MS analysis, our study provides clear evidence that iPA is 
effectively internalized into endothelial cells in a time-dependent manner 
and is converted to its 5'-monophosphorylated form iPAMP by the ADK 
enzyme (Fig. 12); thus, it can be considered an AMP mimetic. Only one 
study, published 40 years ago, suggested, from data obtained in a cell-free 
system, that iPA could be a substrate of ADK (Divekar et al., 1974). We 
have demonstrated for the first time that blocking ADK activity with its 
potent inhibitor 5-Itu (ki=30 nM) prevented all the effects of iPA on 
endothelial and melanoma cells, clearly indicating that phosphorylation of 
iPA into iPAMP is essential for its biological activity, as previously 
suggested in other cell systems (Divekar et al., 1974) and similar to the 
process described in plants (Mok and Mok, 2001). Indeed, in Dictyostelium 
discoideum, the synthesis of iPA is catalyzed by the enzyme isopentenyl 
transferase (IPT), which transfers the isoprenoid moiety from DMAPP to 
AMP, thus producing iPAMP in equilibrium with its nonphosphorylated 
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form iPA (Golovko et al., 2000). Moreover, we showed that ADK 
inhibition by 5-Itu effectively prevented the formation of iPAMP, 
increasing the iPA/iPAMP ratio inside the cells. 5-Itu, at the very low 
concentration used in our experimental setting (30 nM, 30 min), has been 
widely documented to be selective for ADK inhibition, whereas at higher 
concentrations (10–50 µM), it has been shown also to inhibit nucleoside 
transport (Sinclair et al., 2001). We indeed observed a slight decrease in 
iPA internalization after 5-Itu pretreatment (Fig. 12), but this effect was 
probably due to an alteration of the concentration gradient between the 
outside and inside of the cell, with an accumulation of nonphosphorylated 
iPA inside the cell that delays iPA entry for an inversion of the gradient, as 
happens with nucleosides (Sinclair et al., 2001). As expected, we found 
that iPAMP, behaving as an AMP mimetic, activated the key metabolic 
enzyme AMPK, thus inhibiting the angiogenic process. Also AMPK 
activation was completely reversed by pretreatment with 5-Itu (Fig. 13). Of 
note, all treatments for each experiment were performed with endothelial 
cells grown in serum containing medium; hence, an increase in AMPK 
activity cannot be attributed to metabolic stress. AMPK is active under 
conditions that deplete cellular ATP and elevate AMP, such as long-term 
nutrient starvation, hypoxia, ischemia, heat shock, and exercise (Lee et al., 
2012). In addition to allosteric activation, AMPK activity can be regulated 
by AMP mimetics, such as the cell-permeable activator 5-aminoimidazole-
4-carboxamide riboside (AICAR). As we observed in our study for iPA, 
AICAR has been reported to be rapidly taken up by cells and 
phosphorylated by ADK to 5-amino-4-imidazolecarboxamide 
ribonucleotide (ZMP), behaving as an AMP analogue that mimics the 
effect of the substrate AMP on AMPK activation (Corton et al., 1995), by 
competing with AMP for binding to the regulatory-subunit (Zou and Wu, 
2008). Indeed, the ZMP proapoptotic effect in liver cells was completely 
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blocked by 5-Itu, as we observed in endothelial cells treated with iPA. 
Although the ability of AMPK to preserve endothelial cell viability is well 
known, the role of AMPK in regulating endothelial cell proliferation is not 
as well understood and depends largely on the nature and length of the 
angiogenic stimulus (Reihill et al., 2011). In particular, chronic activation 
of AMPK, such as that observed in our model where AMPK activation was 
sustained up to 24 h, may favor endothelial cell growth arrest. On the 
contrary, acute, transient activation of AMPK in response to angiogenic 
factors, such as VEGF or erythropoietin, may be involved in the induction 
of proliferation (Stahmann et al., 2010). It is known that AMPK exerts a 
protective effect on endothelial cells under conditions such as metabolic, 
oxidative, or inflammatory stress, mainly through the activation of eNOS 
(Nagata et al., 2003). On the other hand, the ability of AMPK to inhibit 
angiogenesis, an ATP-consuming process, represents the classic facet of 
the energy-preserving role of this kinase. AMPK activation is considered a 
promising strategy for the treatment of metabolic diseases such as type II 
diabetes and obesity and cardiovascular and neurologic diseases. It is also 
emerging as an interesting potential treatment in cancer, as a downstream 
target of the tumor suppressor LKB1 and because of its regulatory effects 
on mTOR, which is aberrantly activated in many tumors (Laplante et al., 
2012). Recent studies have demonstrated that AMPK activation (e.g., by 
AICAR or expression of constitutively active mutants) inhibits cancer cell 
proliferation and/or induces apoptosis in several cancer models and in 
myocardial cells and keratinocytes (Theodoropolou et al., 2010; Vakana et 
al., 2011). In our study, iPA treatment at the highest concentrations (5 and 
10 µM) exerted proapoptotic effects (Fig. 14). The activation of the 
intrinsic apoptosis pathway was confirmed by the caspase cascade, which 
leads to caspase-9 activation followed by caspase-3 activation and results 
in PARP-1 cleavage, finally leading to apoptotic cell death. We found that 
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iPA induced the activation of typical DNA damage checkpoints, such as 
the ATR-Chk1 pathway and p53. We hypothesize that the putative 
triphosphate derivative of iPA, similarly to false bases such as 5-
fluorouracil (5-FU), is misincorporated into RNA, causing alterations of its 
processing and functioning, or into DNA, resulting in DNA damage and 
checkpoint activation. This effect may also be related to AMPK activation, 
in that it has been reported that the activation of AMPK is associated with 
the phosphorylation of p53 (Ser15 and Ser20), which is coupled to its 
acetylation (Lee et al., 2012). Indeed, we found that iPA induces the 
phosphorylation of p53 on Ser15 (Fig. 14). Moreover, recent works 
describe a novel function for AMPK as a sensor of genomic stress and a 
participant of the DNA damage response (DDR) pathway (Sanli et al., 
2013).  
High interest is emerging in developing AMPK agonists for clinical use as 
antitumor agents. Moreover, blocking of endothelial cell proliferation and 
migration by AMPK activation is of potential pharmacological 
significance, because these processes contribute to several pathologic 
disorders in addition to cancer, such as atherosclerosis, diabetic 
retinopathy, and several autoimmune diseases (Folkman, 2006). Among 
the AMPK activators actually studied, there are also the selective small 
molecule A-769662, which directly binds and activates the kinase in a 
mode similar to AMP (Goransson et al., 2007) and metformin, the most 
widely prescribed oral hypoglycemic agent, which activates AMPK in 
endothelial cells by a complex mechanism that probably involves the 
inhibition of mitochondrial respiration, with a consequent elevation of the 
AMP/ATP ratio (Zhou et al., 2001). It is noteworthy that retrospective 
studies conducted in diabetic patients found that metformin is associated 
with a decreased risk in developing cancer and a better response to 
chemotherapy (Landman et al., 2010). Available AMPK activators, such as 
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metformin and AICAR, show relatively low efficacies. Indeed, metformin 
activates AMPK at millimolar levels, whereas AICAR acts at low 
millimolar concentrations (0.5–2 mM) (Meisse et al., 2002). The advantage 
of iPA with respect to these AMPK activators is a higher efficacy, with 
low micromolar concentrations effective in activating AMPK and exerting 
biological effects, such as the angiogenesis inhibition described herein or 
the tumor growth blockade (Bifulco et al., 2008). In our work, iPA clearly 
displayed antiangiogenic properties through AMPK-dependent 
mechanisms; however, we have to take into account that it may also elicit 
other effects, as demonstrated elsewhere. Indeed, iPA inhibits breast and 
colon cancer cell proliferation, affecting, respectively, the Akt/NFkB cell 
survival pathway and inducing JNK phosphorylation and hence activation 
(Laezza et al., 2009; Laezza et al., 2010). Both these signaling pathways 
are involved in apoptotic events downstream AMPK activation in several 
cancer models (Zheng et al., 2012; Yung et al., 2013). Furthermore, among 
the proposed mechanisms that explain the antiproliferative effects of iPA, 
inhibition of the mevalonate pathway enzyme FDPS, and hence of 
prenylation of key oncogenic proteins such as Ras and Rho, is noteworthy 
(Laezza et al., 2006). Of further interest, AMPK activation is involved in 
the regulation of lipid metabolism, being linked to the inactivation of 
acetyl-CoA carboxylase and of 3-hydroxy-3-methyl-glutaryl-CoA 
reductase, a limiting enzyme of the mevalonate pathway. The importance 
of interfering with the mevalonate pathway to arrest cancer growth is 
highlighted by the antitumor properties shown by several classes of drugs 
targeting this pathway, such as statins, bisphosphonates, and 
farnesyltransferase inhibitors (Laezza et al., 2008). 
Our results demonstrating that iPA elicits a direct antimigratory action on 
endothelial cells (Fig. 15) are in agreement with those in recent articles 
reporting the inhibition of the migration of HUVECs, monocytes, and 
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neurons by AMPK activation (see enclosed Picardi et al., 2013). Also, in 
the case of migration, transient AMPK activation by VEGF is associated 
with endothelial cell migration stimulation through eNOS (Reihill et al., 
2011; Nagata et al., 2003). Therefore, as is true of proliferation, the reasons 
for the disparate effects of AMPK on cell migration are strictly dependent 
on the activating stimulus, the metabolic status, and the degree of AMPK 
activation. Of note, iPA may exert an antimigratory effect, also affecting 
cAMP-mediated microfilament organization, as has been observed in 
thyroid cancer cells (Laezza et al., 1997), or through matrix 
metalloproteinase inhibition, as reported for AMPK activators (Laplante et 
al., 2012). AICAR has been shown to inhibit angiogenesis in vitro (Peyton 
et al., 2012) and in vivo, reducing retinoblastoma neovascularization, even 
if this effect is the consequence of tumor mass reduction rather than a 
direct effect on the vasculature (Theodoropoulou et al., 2013). In our study, 
we demonstrated that iPA directly affects angiogenesis, not only in vitro, 
but also maintains its properties in the in vivo setting, in the absence of 
tumor masses (Fig. 16). Moreover, unlike AICAR, which inhibited 
endothelial cell proliferation and migration in vitro, while paradoxically 
stimulating morphologic differentiation into capillary-like tube structures 
(a fundamental characteristic of the formation of new vessels), iPA 
inhibited all the successive phases of sprouting angiogenesis. 
5.2 N6-isopentenyladenosine, activating AMPK, induces autophagy 
and apoptosis in a cooperative manner in melanoma 
Since angiogenesis is a key step in tumor growth and metastasis providing 
necessary oxygen and nutrients for the tumor (Mazeron et al., 2009), the 
inhibition of any step of these processes that lead to the disruption of 
angiogenesis can be useful as a potential antitumor therapy. In the light of 
this paradigm, the effects of iPA on tumor angiogenesis process were 
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investigated, using A375 human melanoma cells, well known for their 
highly angiogenic phenotype, as well as co-cultures of endothelial and 
melanoma cells. 
Although after 24 hours of treatment iPA did not significantly affect the 
viability of melanoma cells (data not shown), surprisingly melanoma cells 
treated with iPA (1-10 μM) for 24 hours and co-cultured with endothelial 
cells for the next 24 hours inhibited the viability of endothelial cells 
already at 2.5 μM (Fig. 17). When a more sensitive proliferation assay was 
performed, the time- and concentration-dependent anti-proliferative effect 
of iPA was clear (Fig. 18), with a concomitant block in G1 phase of 
melanoma cells cycle (Fig. 19). 
In a recent study the authors hypothesized that the antiproliferative effects 
of iPA on prostate cancer cells could be mediated by adenosine receptor 
A3. In that study iPA is shown as agonist of A3 receptors, binding 
selectively to this isoform of adenosine receptors (Blad et al., 2011). A3 
receptors are expressed also on A375 melanoma cells. Stimulation of these 
receptors activates PI3K inducing thus Akt activation, with concomitant 
decrease of ERK1/2 levels (Merighi et al., 2005). The authors conclude 
that the antiproliferative effects of iPA in the range of 10-100 nM on 
prostate cancer cells could be mediated by A3 receptors. Of note, in this 
range of concentrations iPA did not exert any antiproliferative effects in 
melanoma cells. The same authors speculated that iPA in the higher range 
of concentration (micromolar range) exerts its antiproliferative effects 
independently of A3 receptors (Blad et al., 2011). In our work 
antiproliferative effects of iPA observed in melanoma cells are in the 
micromolar range (1-20 µM) and for these reasons we exclude any 
involvement of the adenosine pathway, as already shown for endothelial 
cells system. In our opinion, iPA does not act as agonist or antagonist of a 
G-protein coupled receptor as A3 in extracellular environment, but it 
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indeed enters into the cells where is monophosphorylated in 5'-
monophosphate isopentenyladenosine (iPAMP), its active form. Indeed, as 
observed in endothelial cells, the phosphorylation of iPA in C5 by ADK is 
crucial also to the anti-tumor activity of iPA, since the pre-treatment with 
5-Itu reverted all its biological effects. Indeed, the active metabolite is 
precisely iPAMP, an AMP mimetic. According with what highlighted in 
endothelial cells, iPAMP was able to induce the phosphorylation and hence 
activation of AMPK also in melanoma cells (Fig. 20). The AMPK pathway 
appears to be involved in cell death and more specifically in autophagy 
induced by nutrient deprivation, growth factor withdrawal and hypoxia. 
Among proposed mechanisms, the activation of AMPK leads to the 
suppression of mammalian target of rapamycin (mTOR), thereby 
activating autophagy (Wang and Qin, 2013). Autophagic cell death (also 
referred as type II cell death) and apoptosis, known as type I cell death, 
have considered as the principal mechanisms of programmed cell death in 
mammals. Although autophagy and apoptosis are markedly different 
processes, they can act together to induce cell death in a coordinated and 
cooperative manner. Autophagy is emerging also as an escape mechanism 
associated to chemoresistance that cancer cells can exploit for protection 
against a variety of intrinsic and extrinsic stress signals, including 
chemotherapeutic agents (Farkas et al., 2011). However, excessive or 
derailed autophagy can also favor cell death. How these two seemingly 
opposing roles of autophagy can have an impact upon cancer 
chemoresistance is unclear (Wang and Qin, 2013). Some recent reports 
have implicated AMPK with regulation of autophagy. In colon cells, for 
example, autophagy, but not apoptosis, is considered as a major cause for 
C6 ceramide-induced cytotoxic effects and activation of AMPK/Ulk1 is 
required for the process (Huo et al., 2013). Activation of AMPK induces 
autophagic cell death in a great number of tumors also in vivo (Meley et 
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al., 2006; Xu et al., 2007; Vara et al., 2011; Salazar et al., 2011; Din et al., 
2012; Liu et al., 2012). Also in endothelial cells AMPK-induced autophagy 
is observed (Wang et al., 2011; Zhang et al., 2013). On the other hand, a 
work reported that AICAR treatment and glucose deprivation of human 
mammary cancer derived cells (MCF-7s) is able to inhibit autophagy 
(Liang et al., 2007). Interestingly, more recent studies indicate that 
apoptosis and autophagy via a mitochondrial-mediated ROS–p38–p53 
pathway have been observed in melanoma cells (Liu et al., 2008). The 
activation of AMPK is also involved in cell apoptosis induced by different 
stimuli including chemotherapy drugs (Kim et al., 2010; Lee et al., 2010) 
and in vincristine treated murine melanoma cells, probably by the 
activation of p53 and the inhibition of mTORC1 that is a complex 
composed by a serine/threonine kinase called mTOR, regulatory associated 
partner of mTOR (raptor) and mLST8 (lethal with sec thirteen), together to 
ROS production and LKB1 activation (Chen et al., 2011). 
As reported above, there is a tight interconnection between unfolded 
protein response (UPR) and autophagy. Indeed, accumulating data indicate 
that ER stress is also a potent trigger of autophagy and there are evidences 
of an involvement of AMPK (Høyer-Hansen and Jäättelä, 2007). 
Interestingly, a recent work highlighted that iPA was able to induce 
cellular stress in vitro upregulating the genes belonging to gene ontology 
(GO) category, among others, just “unfolded protein response” (Colombo 
et al., 2009). Employing microarray analysis, the authors reported that iPA 
(100 µM for 6 hours) was able to upregulate this specific GO category in 
human lung and breast cancer cells. In our experimental setting, autophagy 
pathway is evidently activated treating melanoma cells in a range of 
concentrations very low (up to 10 µM) with respect to the cited work. 
These data, anyway, could be supported by previously evidences, showing 
a correlation between these upregulated genes and the trigger of 
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autophagy. In the same study, microarray analysis revealed also an 
involvement of the genes belonging to “cell cycle arrest” GO category. 
Moreover, cell cycle arrest in G0/G1 phase has been recently reported in 
bladder carcinoma cells treated with iPA (Castiglioni et al., 2013). These 
data are concordant with the cell cycle arrest in G1 phase that we have 
reported also in melanoma cells after iPA treatment (Fig. 19).  
It is now well accepted that basal or low level of autophagy is responsible 
to protect cells from apoptosis depending on the physiopathological setting 
(Levine and Yuan, 2005; Gozuacik and Kimchi, 2004; Codogno and 
Meijer, 2005; Sato et al., 2007; Vara et al., 2011). On the other part, 
excessive or sustained autophagy causes cell death when cell faces 
significant stress conditions (Rosenfeldt and Ryan, 2011). Notably, 
autophagy does not always promote cell survival, but can also mediate 
non-apoptotic cell death for example in experimental conditions where 
apoptosis pathways are blocked, or in response to treatments that 
specifically trigger caspase-independent autophagic cell death. Thus, 
apoptosis or/and autophagy are interesting mechanisms to induce cancer 
cell death. To determine whether autophagy mediated by iPA could affect 
cell viability, we analyzed the percentage of apoptotic cells (Annexin V 
positive and Annexin V/PI double positive) after 24, 48 and 72 hours with 
increasing concentrations of iPA. The substantial induction of apoptosis 
was clear after 48 and aven more after 72 hours of treatment with iPA (Fig. 
19B). Taken together, these results indicate that iPA induces a concomitant 
induction of autophagy (Fig. 21) and apoptosis processes in melanoma 
cells, both of which are involved in cell death. To identify the event 
sequence of autophagy and apoptosis, we have performed the analysis of 
biochemical pathways in time course. The results clearly showed that the 
increase of expression and the conversion of LC3 preceded the cleavage of 
PARP (Fig. 22), suggesting that the autophagy is set up before apoptosis, 
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in according with that flow cytometry analysis highlighted (Fig. 21). 
These findings are consistent with results of a work showing that the 
AMPK activators AICAR and metformin reduced the proliferation of 
SKMel2 and SKMel28 melanoma cells. Metformin action is mainly 
mediated by AMPK activation (Woodard et al., 2010). However, very little 
is known about the role that the interchange between these two cellular 
processes have in the control of tumor growth in response to anticancer 
agents. Nevertheless, further research will be still necessary to clarify the 
precise mechanisms linking both death processes. 
Undoubtedly, in cancer there are multiple functional relationship reported 
between apoptosis and autophagy, and these processes separately or/and 
jointly seal the fate of the cell (Maiuri et al., 2007). The discovery of new 
therapeutic compounds is a very important challenge to treat advanced 
melanomas that are became resistant to existing therapies. 
5.3 N6-isopentenyladenosine directly affects cytotoxic and 
regulatory functions of human NK cells 
Among the others, immune-surveillance plays a role in the control of 
tumor development. Belonging to innate immunity, NK cells are cytolytic 
lymphocytes that can directly kill transformed and microbe-infected cells. 
Despite the prevailing view that immunological surveillance is triggered by 
danger signals, injured cells arising signals, toxins, pathogens and 
mechanical damage, a recent work has shown that locally resident immune 
cells in the skin can detect early signs of cellular stress, through the 
recognition of ligands on premalignant cells, thus overting tumor 
transformation (Strid et al., 2008). NK cells reside in the skin (Luci et al., 
2009), thus melanocytes are susceptible to NK cell recognition from early 
stages of dysregulation. Although there is the potential for early NK cell 
recognition of transformed melanocytes, some studies have indicated that 
NK cells are poorly represented among tumor-infiltrating lymphocytes 
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during melanoma progression, whereas others have demonstrated NK cells 
in all biopsies evaluated. Understanding how NK cells migrate into the 
tumor microenvironment is important to redirect NK cells to the tumor in 
the therapeutic setting. To appreciate the role of immunosurveillance 
during melanoma, the factors that influence NK cell recognition of nascent 
dysregulated melanocytes need to be identified. In turn, how these factors 
change at different stages of disease, both in primary lesions and 
metastases, must be deciphered. This involves characterizing the spatio-
temporal expression of ligands during melanomagenesis, which hitherto 
has been poorly described, and the consequences of this event on NK cell 
function (Burke et al., 2010). In the light of these observations, in the last 
part of this work, we presented previously unrecognized functions of iPA 
in promoting a direct activation of human resting NK cells and a synergy 
of action with IL-2 in potentiating the effector arm of their responses. Of 
note, a similar synergistic effect has not been observed in NK cells treated 
with the isoprenoid intermediate IPP or with the purine nucleoside 
adenosine (data not shown). This observation correlates with previously 
published findings that IPP and IL-2 do not stimulate NK cells directly, 
rather IPP plus IL-2- induced soluble factors (e.g., cytokines) from γδ T 
cells that can stimulate indirectly NK cell mediated cytotoxicity 
(Alexander et al., 2008). At the same way adenosine, whose levels have 
been found elevated within growing tumors, seems to inhibit effector 
functions of tumor-infiltrating immune cells (Lokshin et al., 2006), mainly 
through the stimulation of the immunosuppressive A2A and A2B 
adenosine receptors subtypes. Even though in an in vivo mouse model the 
oral administration of an A3 adenosine receptor-selective agonist led to 
enhanced NK cell activity (Harish et al., 2003), the direct effect of 
adenosine on IL-12 producing dendritic cells rather than on NK cells has 
been reported to account for the observed effects. On the contrary, the 
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stimulation of peripheral blood lymphocytes (PBMCs) with iPA and low 
doses of IL-2 was not able to selectively expand γδ T cells (data not 
shown) like IPP does, confirming the specificity of action of this molecule 
on NK cells. These findings support the notion that the effects of iPA, in 
all the cell models that we have studied, are retained in its peculiar 
structure made of the specific combination of the adenosine molecule and 
the isoprenoid moiety. And maybe also thanks to the lipophilic nature of its 
isoprenoid chain, iPA can enter inside NK cells, as observed in endothelial 
cells, where it exerts its immunostimulatory activity. According to the far 
away work of Gallo et al., we have seen that also on NK cells sub-
micromolar doses of iPA have a stimulatory effect on cell proliferation and 
activation status, measured by increased levels of CD69 (Fig. 24). 
Remarkably, NK cells did not undergo proliferation by iPA alone (data not 
shown). Moreover, going beyond the preliminary observations of Gallo, 
we investigated to what extent the reported synergistic effect of IL-2 and 
iPA applies only to NK cell proliferation or also holds true for other 
effector functions of NK cells. Consistent with proliferation results, also 
induction of granules’ release and the NK cytotoxic potential against tumor 
target cells, were positively affected by iPA (Fig. 25). In fact, moreover 
besides their ability to kill aberrant cells, NK cells have the capacity to 
produce a variety of cytokines and chemokines (TNF-α, IFN-γ, CCL3, 
CCL5, IL-8, IL-10 etc), through which they also participate in the shaping 
of adaptive immune response (Vivier et al., 2009). These NK cell effector 
functions are regulated by multiple activating and inhibitory NK cell 
receptors (Lanier, 2005). Engagement of activating receptors, such as 
natural cytotoxicity receptors (NCRs; NKp30, NKp44, and NKp46) and 
NKG2D, leads to the activation of a variety of downstream signaling 
molecules, which result in the activation of MAPKs, particularly ERK, 
which are crucial for cytolytic granule release and cytokine generation 
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(Vivier et al., 2004). 
Then we provided evidence, at least in part, of the selective involvement of 
NKp30 and to a minor extent of NKG2D, in mediating in particular iPA-
IL-2 synergic effects on cytotoxicity (Fig. 25). Of note, the engagement of 
NKp30 and NKG2D by K562 cells that express cognate ligands for these 
natural cytotoxicity receptors (Brandt et al., 2009; Joyce et al., 2011) have 
been shown to induce not only cytotoxic effector mechanisms, but also the 
secretion of cytokines and chemokines (Fauriat et al., 2010). These 
findings, along with the recent report highlighting that the engagement of 
NKp30 on Vδ1 T cells triggers the production of high levels of 
CCL3/MIP-1α, CCL4/ MIP-1β, and CCL5/Rantes (Hudspeth at al., 2012) 
is in agreement with our results showing the ability of iPA low doses, after 
co-incubation with K562 cells, to stimulate not only the secretion of IFN-γ 
and TNF-α cytolytic cytokines, but also of chemokines like CCL3 and 
CCL5. The classic cytolytic cytokines may account for the observed 
enhanced cytotoxicity of IL-2 primed NK cells, whereas the chemokines 
may be useful to the complete host control of infections and tumor growth 
through the mobilization of immunocompetent cells to sites of infections 
and tumoral lesions (Lavergne et al., 2004; Thapa et al., 2008). If there is a 
concentration-dependent effect in the secretion of IFN-γ, the same has not 
been seen for chemokines, probably because their secretion requires only 
stronger activating stimuli (e.g. 0.1 μM dose), or simply because of the 
very high inter-individual variability of cytokine milieu of donors where 
may coexist different factors that can regulate the delicate balance in NK 
cell responsiveness to the two iPA doses. Moreover, the current vision of 
CD56dim NK cells as the rapid more prominent producers of cytokines 
and chemokines upon both target cell recognition (Fauriat et al., 2010) and 
exogenous cytokine activation (De Maria et al., 2011) led us to also verify 
which NK subset iPA might selectively target. Accordingly, 
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multiparametric intracellular staining revealed that IL-2 primed CD56dim 
NK cells were preferentially expanded and activated to secrete IFN-γ by 
iPA costimulation upon K562 short-term co-colture (data not shown). A 
molecular target candidate to mediate the action of iPA seems to be the 
ERK1/2 MAPK, whose phosphorylation status in human primary NK cells 
increased in response to the different concentrations of this isoprenoid 
compound. Our data show, in fact, that iPA positively modulates only 
ERK1/2 signal transduction, without affecting the STAT5-dependent 
pathways that could be fully operational in iPA-treated NK (Fig. 27). This 
was corroborated by the observation that the treatment of IL-2 primed NK 
cells with different concentrations of iPA does not change even the levels 
of p38 phosphorylation, which is crucial for the generation of cytokines 
upstream STAT5 signaling (Pujari et al., 2010). We further corroborated 
the role of ERK1/2 activation for cytolytic activity and cyto-chemokines 
generation using the UO-126 MEK inhibitor, that completely ablated the 
NK positive response to the co-treatment with IL-2 and iPA (Fig. 28). 
Activation of ERK follows a highly conserved set of molecular events and 
Ras protein is an essential factor in MAPK regulation (Mor and Philips, 
2006). Accordingly to literature, we have found that the co-treatment with 
the stimulatory dose of iPA effectively led to greater levels of the active 
form of Ras, compared to the effect of IL-2 alone (Fig. 29). Of note, we 
started to know that the stimulatory action of iPA converges on ERK1/2 
MAPK through the modulation of expression and activity of farnesyl 
diphosphate synthase (FDPS), the same enzyme implicated in the 
stimulation of the cytotoxic γδ T cells. Indeed, previous experimental 
observations by our group suggested that iPA could interfere with the cell 
growth of xenograft tumors induced by k-Ras transformed thyroid cells 
(KiMol), by inhibiting FDPS activity and hence downstream protein 
prenylation (Laezza et al., 2006), which suggests that this isoprenoid end 
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product might be used for antineoplastic therapy, an application emulating 
that of statins and/or FDPS inhibitors like bisphosphonates, as well as 
farnesyl transferase inhibitors (Thurnher et al., 2012). iPA has been 
reported to regulate FDPS also in fibroblasts from humans with progeroid 
syndromes, where the inhibition of the farnesylation of prelamin A is 
associated with a decrease in the frequency and nuclear shape 
abnormalities, making iPA a potential strategy for treating children with 
Hutchinson-Gilford progeria syndrome (Bifulco et al., 2013). In the present 
work, lowest doses (up to 1 μM) of iPA resulted in a surprising and 
effective boosting of NK activity. At these doses, iPA was able to enhance 
both the protein level expression and the enzymatic activity of FDPS. 
However how iPA exerts its effects remains to be further clarified. We 
believe that our findings can give us a satisfactory explanation of the 
stimulatory activity of iPA on human NK cells. Indeed, the FDPS 
activation can cause an accumulation of farnesylpyrophosphate (FPP) and 
of its downstream product geranylgeranylpyrophosphate (GGPP), both 
essential for the biological functions of the prenylated proteins (Thurnher 
et al., 2012). Prenylation occurs on many members of Ras and Rho family 
of small guanosine triphosphatases (GTPase) containing the CaaX 
sequencing, but also on many members of the Rab family of Ras-related 
G-proteins. Interestingly the activation of Rac, a member of Rho GTPase 
family, is seen as a booster for the effector cell-binding efficiency, 
recruitment ability, and consequently, cytotoxic activity in NK cells, 
through the regulation of the actin/microtubule interplay (Malorni et al., 
2003). In this context, people affected by the Wiskott-Aldrich disease, a 
human pathology characterized by a defect in a protein controlled by the 
Rho family member Cdc42 (Wiscott-Aldrich syndrome protein [WASP]), 
exhibit an impaired NK cell function (Orange et al., 2002). At the same 
way, the absence of Rap1b, a small-molecular weight GTP-binding protein 
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that belongs to the Ras-like superfamily of GTPases, impaired NKG2D, 
Ly49D, and NCR1-mediated cytokines and chemokines production by NK 
cells of knockout mice (Awasthi et al., 2010). Moreover, isoprenylation 
has been proved to be important for the induction of elevated LFA-1 
affinity and avidity in NK cells (Raemer et al., 2009), that was particularly 
important for IFN-γ secretion. Finally, it has been reported that a reduced 
Ras activity by the knockdown of Ras guanyl nucleotide-releasing protein 
(RasGRP), impaired NK cell effector functions affecting the Ras-MAPK 
pathway (Lee et al., 2009), generally sustained by all these isoprenylated 
proteins. Thus, in our opinion, iPA by increasing FDPS activity can expand 
and co-stimulate human NK cells regulating the rate of prenylation of key 
proteins in NK cell activation processes, like Ras, Rac, Rap1b, that signal 
through ERK1/2. Remarkably, this is not the first evidence that 
intermediates of the mevalonate pathway are able to expand the immune 
cytotoxic compartment; just we think about the enhanced expansion of Th1 
effector cells seen to be promoted by accumulation of farnesyl-PP (Dunn et 
al., 2006), or simply to the expansion of γδ T cells following IPP plus IL-2 
stimulation (Maniaret et al., 2010). Overall our data reflect the important 
action of iPA on the entire complexity of NK cell functions even though 
some questions need to be deepened in future. First of all if in a 
physio/pathological context in vivo iPA could be endogenously modulated 
in NK cells or if the NK activation could be rather largely dependent from 
an extracellular source of iPA, as suggested by the detection of iPA in 
human urine from normal subjects and cancer patients (Vold et al., 1982). 
Moreover, the upregulation of FDPS by iPA may not represent the unique 
mechanism responsible of iPA effects in NK cells and other potential 
molecular targets remain to be identified. This could help to explain some 
apparently paradoxical results, as for example, the observation that iPA 
treatment of IL-2 stimulated NK cells increases their proliferative potential 
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and IFN-γ production over that of IL-2 stimulation alone (Fig. 26), while it 
is not able to induce the same when used alone on resting NK cells (Fig. 
21). The addition of IL-2 results in a morphologic and biological 
transformation to a fully activated NK cell capable of DNA synthesis, 
eventual mitosis, cyto-chemokines production and cytotoxicity. These 
events are preceded, of course, by an increase in RNA and protein 
synthesis. Gene expression profile analysis of iPA-treated cells revealed 
that the majority of modulated genes were those involved in transcription 
and its regulation (Colombo et al., 2009). Depending on the cytokines 
milieu or resting condition, iPA might then influence a specific gene 
expression program in NK cells (Ramirez et al., 2012). This could explain 
also the selective effect of iPA on the up-regulation of NKp46 (Fig. 23), 
whose high expression specificity on NK cell lineage, unlike other NCRs, 
needs a specific and fine transcriptional control (Lai and Mager, 2012), 
which iPA could affect. Collectively, the emphasis on this small isoprenoid 
product is that it could represent a novel endogenous signal able to 
complement the well characterized IPP-induced γδ T cells expansion, in 
order to achieve a combined and finely tuned innate artillery against 
infections and cancer.  
Our findings highlighted a new mechanism of iPA anti-tumor action. In 
addition to this scenario, we can speculate that the pharmacological 
induction of IPP and iPA levels could lead to a collaborative reaction by 
activating respectively human γδ T cells and NK cells, that will be 
interesting to explore in more detail in different physiopathological 
contexts. 
 





N6-isopentenyladenosine (iPA) is a modified adenosine characterized by 
an isopentenyl chain linked to the nitrogen at position 6 of the purine base. 
The isoprenoid chain derives from a product of the mevalonate pathway 
and, more specifically, from dimethylallyl pyrophosphate (DMAPP), 
which is in equilibrium with its isomer, isopentenyl pyrophosphate (IPP). 
iPA belongs to the family of cytokinins that regulate plant cell growth and 
differentiation, but it is also present in mammalian cells in a free form in 
the cytoplasm or bound to tRNA. iPA biosynthesis in mammals has not 
been fully disclosed, whereas some of its biological effects are known. 
Antiproliferative and pro-apoptotic effects of iPA have been reported 
against various tumors in vitro and in vivo (Bifulco et al., 2008). 
 
 
Figure 30. Proposed mechanism of action of iPA in endothelial cells 
 




In this study new pleiotropic effects of iPA have been reported for the first 
time. Specifically, iPA, in the range of 1-10 µM, can be considered as a 
novel AMPK activator, in its 5'-monophosphorylated form (iPAMP) acting 
thus as an AMP mimetic. Indeed, AMPK activation is related to the 
inhibition of all the key steps of the angiogenesis process, including 
proliferation, migration, invasion and tube formation in endothelial cells, 
finally leading to the activation of apoptosis (Fig. 30). 
Therefore, iPA could represent a useful tool for the inhibition of 
neovascularization in cancer and in other diseases where excessive 
neoangiogenesis is the underlying pathology, as atherosclerosis, diabetic 
retinopathy, obesity. Of note, neither isopentenyl pyrophosphate nor 
adenine or adenosine have similar behaviors. Thus, it’s the entire 
molecular structure of iPA responsible for all the biological effects 
observed. 
In melanoma cells AMPK activation can be considered responsible of the 
arrest of cancer cells growth, autophagy induction and subsequent 
apoptosis (Fig. 31). In this system, indeed, autophagy is not correlated to 
cell survival and thus chemoresistence, but it really represents a cell death 
II type. This aspect can be very useful for the melanoma cancer therapy. 
Obviously, further experiments will be necessary to validate in animal 
models these in vitro data. 
 




Figure 31. Proposed mechanism of action of iPA in melanoma cells 
 
In the last part of this work an additional piece of evidence of the immune-
regulatory function of iPA, at submicrolar concentrations, has been 
reported. iPA was able, indeed, to stimulate directly the proliferation of 
NK cells, activating their potential cytotoxicity against tumor cells. The 
molecular mechanism by which iPA exerts its effects could be related to 
the activation of Ras (Ras-GTP), responsible then for the activation of 
MAPK signaling. It was reported also an activation of FDPS, probably 
involved into the activation and functionality of Ras through its 
isoprenylation (Fig. 32). 
 




Figure 32. Proposed mechanism of action of iPA in Natural Killer cells 
 
The novel and intriguing insights of this study highlight pleiotropic effects 
of this isoprenoid derivative, making iPA an interesting lead compound for 
a new class of antitumoral drugs. Indeed, while the anticancer effects in 
vitro are well-documented, iPA efficacy in vivo is limited by its 
pharmokinetic properties, since when administered intraperitoneally in 
mice it is quickly catabolized in plasma (Colombo et al., 2009). Of note, 
when administered subcutaneously, iPA is able to inhibit cancer growth of 
tumor xenografts, even at lower doses (Laezza et al., 2006). Among the 
possible enzymes responsible for the inactivation of iPA, adenosine 
deaminase doesn’t seem to be involved, since iPA is not a substrate of this 
enzyme as we have shown (Fig. 12). Among the enzymes involved in 
catabolism of iPA, purine nucleoside phosphorylase could be responsible. 
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New iPA derivatives are necessary to identify a compound with better 
pharmacokinetic profile and enhanced in vivo antitumor activity. 
In the light of overall results, iPA is an attractive pharmacological tool for 
the anticancer strategy, because of its ability to inhibit cancer growth and 
proliferation both directly on tumor cells and indirectly, by the inhibition 
of the angiogenic process indispensable to cancer growth and progression. 
Moreover, iPA can be useful in immune intervention, in particular in the 
field of anti-tumor immunity, since it has been proven stimulating and 
activating directly natural killer cells. In this way a multifactorial and 
cooperative strategy of attack of the neoplastic mass could be carried out. 
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